Investigation of Rice Bran Derived Anti-cancer Pentapeptide for Mechanistic Potency in Breast Cancer Cell Models by Li, Ruiqi




Investigation of Rice Bran Derived Anti-cancer
Pentapeptide for Mechanistic Potency in Breast
Cancer Cell Models
Ruiqi Li
University of Arkansas, Fayetteville
Follow this and additional works at: http://scholarworks.uark.edu/etd
Part of the Cell Biology Commons, Food Chemistry Commons, and the Oncology Commons
This Thesis is brought to you for free and open access by ScholarWorks@UARK. It has been accepted for inclusion in Theses and Dissertations by an
authorized administrator of ScholarWorks@UARK. For more information, please contact scholar@uark.edu, ccmiddle@uark.edu.
Recommended Citation
Li, Ruiqi, "Investigation of Rice Bran Derived Anti-cancer Pentapeptide for Mechanistic Potency in Breast Cancer Cell Models"











Investigation of Rice Bran Derived Anti-cancer Pentapeptide for Mechanistic Potency in Breast 






Investigation of Rice Bran Derived Anti-cancer Pentapeptide for Mechanistic Potency in Breast 
Cancer Cell Models 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of 







Southwest University for Nationalities 
Bachelor of Science in Food Science and Engineering, 2011 
 
May 2014 
















_____________________________                _________________________ 
Dr. Kristen E. Gibson                                   Dr. Jackson Lay, Jr. 
Committee Member                                   Committee Member 
 
_____________________________ 






Bioactive peptides derived from food sources with anti-proliferative properties against 
cancer have drawn more attention in recent years. A pentapeptide derived from rice bran has 
shown anti-proliferative propertiesagainst human breast cancer cells. The objective of this study 
was to investigate the mechanistic action of the pentapeptide-induced apoptosis in breast cancer 
cell models (MCF-7 and MDA-MB-231). The growth inhibit on activity of the pentapeptide was 
evaluated by MTS[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt] assayand trypan blue assay in a dose- and time-dependent manner. 
The apoptotic properties of pentapeptide-induced apoptosis on cancerous breast cells were 
evaluated by morphological changes, DNA fragmentation, and caspases-3/7, -8,and -9 activities. 
The levels of molecular targets (p53, COX-2, TNF-α, Fas, Bax, Bcl-2, and ErbB-2) were 
evaluated by enzyme-linked immunosorbent assay (ELISA) kits. Pentapeptide showed growth 
inhibition activities on MCF-7 and MDA-MB-231 cells. Apoptotic features including 
morphological changes,DNA fragmentation, and caspases ctivation were observed in both cells 
lines after pentapeptide treatment. Decreased levels of COX-2, Bcl-2, and ErbB-2 and increased 
levels of p53, TNF-α, Fas, and Bax expression were detected after cells exposed to pentapeptide 
from 72 to 96 hr. The results suggest that the pentapeptide inhibits growth of human breast 
cancer cells by introducing apoptosis through a caspase-dependent pathway. The pentapeptide 
amplifies the death signal by down-regulating the expr ssion of ErbB-2 in both cell lines and 
COX-2 in ER (Estrogen Receptor)-positive MCF-7 cells. This study provides insight on the 
molecular mechanism of action of the pentapeptide against breast cancer cells. After further 
animal and human clinic trial, the pentapeptide has t e potentiality to be analternative strategy to 
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 Rice (Oryza sativa) is one of the most important staple foods. In the United States, the 
production of rough rice was 265.9 million cwt in 2013 with 130.1 million cwt produced in the 
state of Arkansas (National Agricultural Statistics Service 2013). Rice bran is the aleurone layer 
of the brown rice kernel. During the production of white rice, bran is removed from the kernel by 
friction. Bran accounts for about 10% of rough rice (Parrado et al 2006).  
 Traditionally, rice bran is an underutilized component of rice primarily used as a 
livestock feed supplement and natural oil extraction source in food industry. Protein is an 
important component in rice bran. Rice bran protein accounts for 12-16% of total weight, along 
with dietary fiber (10-27%), and lipid (12-23%) (Wiboonsirikul et al 2008). Among all of the 
cereal bran derived proteins, rice bran protein has a unique nutritional value due to its high 
protein contentand high protein efficiency ratio (PER) of 2.0 to 2.5 compared with casein at 2.5 
(Burks and Helm 1994).   
In western countries, breast cancer is the leading cause of cancer death in women causing 
of over 39,990 deaths in 2013 (Cancer Facts & Figures 2013). Various treatments, such as 
chemotherapy, radiation, and immunotherapy have been applied to kill breast cancer cells by 
inducing apoptosis (Debatin 2000). Bioactive peptides derived from food sources with anti-
cancer proliferation properties have increasingly drawn attention. Hernandez et al (2009) 
demonstrated that lunasin (i.e. a novel and promising chemopreventive peptide derived from 
soybean, wheat, barley, and other plant seeds) showed anti-breast cancer proliferative 
properties.In recent years, hydrolysates and peptids erived from rice bran protein have 
received considerable attention due to the discoveries of some specific anti-disease activities 




Renuka et al 2007; Chanput et al 2009). Kannan et al (2010) isolated a pentapeptide from rice 
bran with potential anti-proliferation activity against several cancers in tissue culture. Those 
studies showed that anti-cancer proliferative agents derived from foods maybe promising new 
candidates for breast cancer therapy.   
             Kannan et al (2009, 2010) reported that rice bran hydrolysates (<5 kDa fraction) 
prepared by enzymatic hydrolysis showed 70-80% anti-prol ferative activity on human breast 
cancer cells. A novel pentapeptide with a Glu-Gln-Arg-Pro-Arg sequence was purified from this 
fraction and showed nearly 80% anti-proliferation abilities on breast cancer cells lines (MCF-7 
and MDA-MB-231) (Kannan et al 2010). However, the mchanism of action in breast cancer cell 
models remains to be investigated. 
              In the present study, the pentapeptid derived from rice bran with anti-proliferative 
activity against breast cancer celllines (MCF-7 andMDA-MB-231)was studied to determine its 
mechanistic action with following specific objectives: 1)to determine the anti-proliferative effect 
of pentapeptide on human breast cancer cell lines; 2) to investigate thepentapeptide-induced 
apoptotic featureson human breast cancer cell lines; 3) to investigate the apoptotic pathways by 






LITERATURE REVIEW  
Food as Medicine 
           According to the national vital statistic  reports in 2013, the leading cause of death in te 
U.S. is heart disease, which accounted for 24.1% of total deaths, followed by malignant 
neoplasms (cancer), chronic lower respiratory diseases, and cerebrovascular diseases with 
percentages of 23.3%, 5.6%, and 5.3%, respectively (Kochanek et al 2013). Aging has become a 
global issue due to the rise of life expectancies and the improvement of medical conditions. 
Obesity is also a critical health issue throughout the world. Approximately one in six adults are 
obese, and more than 48.8% of adults in U.S. are overweight or obese (Overweight & Obesity 
2013).  
            Munoz and Chavez (1998) reported that populations with plant food as a large proportion 
of their diets tend to have a lower incidence of cancer. Other studies also indicate that most 
diseases are preventable and could be minimized by eveloping a healthy lifestyle, which 
includes a proper diet and regular physical activity. Epidemiological studies have shown that 
some flavonoids and other polyphenols in wine or other alcoholic beverages, fruits, and 
vegetables can reduce the risks of heart diseases (St Leger et al 1979, Yano et al 1977, Knekt et 
al 1996). Another recent epidemiology study showed that high fiber and unsaturated fatty acids 
in fruits, vegetables, legumes, whole grains, and fish have protective roles in preventing different 
cancers and cardiovascular diseases. Arnason et al (1981) reported phytochemical constituents of 
plants native to eastern Canada and indicated that at least 105 plants are considered medically 
effective, based on their bioactive compounds such as monoterpenes, polyacetylenes, alkaloids, 
and astringent tannins. Those studies point to potentially significant applications of natural food 
compounds with pharmacological properties to be used as medicine. There is a growing interest 




on their own physical condition, consumers can optimize the healthiness of their diet by eating 
foods which have been formulated or fortified with specific health-promoting nutraceuticals. 
More research is needed in order to uncover the nutritional constituents and underlying 
mechanisms for potential health benefits.  
Bioactive Compounds in Foods 
          “Bioactive compounds” are defined as food constituents with extranutritional value and 
are usually present in small quantities (Kris-Etherton et al 2002). Identification, isolation, and 
characterization of bioactive compounds in foods have been intensively studied. In recent years, 
impressive progress has been made not only in identifying novel bioactives, but also in 
configuring the biological mechanisms of bioactive compounds to reduce the risk of major 
chronic diseases. Table I lists some well known andintensively studied bioactive compounds 
from natural food sources such as fruits, vegetables, c reals, oils, and animal products.  
              Major bioactive compounds in plant foods include phytochemicals, phenolic compounds, 
flavonoids, and isoflavonoids, which have been proven to be effective agents with anti-
carcinogenic properties (Kitts 1994). Another group f important plant bioactives is organosulfur 
compounds, which is mostly present in onions (ANiurn cepa L.) and garlic (Allium sativurn L.). 
Organosulfur compounds have shown several extranutritional properties such as anti-
carcinogenicity, anti-mutagenicity, anti-thromboticity, and lipid-lowering activity (Wargovich 
and Goldberg 1985). Furthermore, numerous bioactives have also been found in, or have been 
produced from, animal products. Most of those are protein hydrolysates and peptides produced 
after enzymatic treatment or fermentation from protein-rich sources such as milk and fish 




9-, and C-12-octadecadienoic acid (CLA) with antioxidative and anticancer properties have been 
found in meats and dairy foods after heating (Ha et l 1987; 1989).                  
Table I. Bioactive Compounds in Fruits and Vegetables, Cereals, Oils, and Animal products1 
Sources Compound name 
Fruits and 
vegetable  
Apples Quercetin, epicatechin, chlorogenic acid, p-coumaric acid, phloridzin 
Citus fruits Naringenin, hesperetin, hesperedin, eriocit in, naringin,  
 
meoeriocitrin, natrituin, p- coumaric acid, caffeic a id, ferulic acid 
Grapes Tannic acid, quercetin, procyanidines, other p nolics 
Onion Quercetin, myricetin 
Carrots Lignin, carotene 
Tomato Quercetin, lycopene, rutin, prunin 
Garlic S-Allyclcysteine, S- allylmercaptocysteine 
Oils 
 
Cocoa Catechin, epicatechin, chlorogenic acid 
Soybean Genistein, daidzein, glycitein, phenolic acds, tocopherols, peptides 
Seame seed Sesamol, sesaminol, tocopherol, sesamolinol 
Cottonseed Quercetin, rutin, kaempferol, gossypeti, h racetin,  
 




Rice Orizanol, isovitexin, cyanidine-3- O- 
Wheat/wheat bran β-D-glycopyranoside, pinoresinol, other phenolics 
Barley  Flavanols (procyanidins); proanthocyanidins 
Oat Esters of caffeic and ferulic acids 
Animal products 
 
Dairy products Omega-3 fatty acids (conjugated linole ic acid) 
Fish Omega-3 fatty acids (alpha-linolenic acid) 
Meat Omega-3 fatty acids (conjugated linolenic acid) 
Yogurt Bacterial cultures 
1Cited from Kris-Etherton et al (2002) and Penningto (2002) 
Protein Hydrolysates and Peptides as Bioactives 
               Proteins, considered the most important building block for life, are also known to 
possess a wide range of nutritional properties. Proteins are one of the major energy sources and 




many dietary protein sources such as egg, dairy products, and seafood, contain compounds with 
specific biological properties that have health-promoting capabilities (Kitts 1993). Among the 
protein derived bioactive compounds, hydrolysates and peptides are major contributors to 
nutraceutical and functional properties (Hartman and Meisel 2007).  
Protein hydrolysates have been used as amino acid crriers for protein digestion deficient 
individuals (Mannheim and Cheryan 1990). The hydrolysates and peptides derived from milk 
and egg have been most intensively studied. Generally, those functional peptides can only be 
activated by release them from the intact protein molecule during gastrointestinal digestion or 
food processing. After release, hydrolysates and peptid s may exert bioactivities in vivo that may 
prevent cardiovascular diseases, decrease the risk of cancer, and exert inverse effects on nervous 
system degradation (Mölleret al 2008).  
Along with the investigation of the bioactivity of protein hydrolysates, studies have 
focused on the characterization of a single peptide that contributes specific health properties. 
Bioactive peptides have special advantages because they: (1) are considered safe and healthy 
compounds since they are derived from natural foods; (2) are easily absorbed with high activity 
because of their low molecular weight; (3) are very stable in different situations; and 4) no 
hazardous immunoreaction result from their simple structures (Sarmadi and Ismail 2010).  
Generally, bioactive peptides are present in the range of 3 to 16 amino acid molecules 
predominately comprised of Val, Leu, Pro, His, Tyr, Glu, and Asp (Saiga et al 2003). Many 
studies have been conducted to prepare, identify, and characterize novel bioactive properties of 
peptides from plant or animal sources like peanut kernels (Hang et al 2010), rice bran (Kannan et 
al 2010, Revilla 2009), sun flower protein (Megias et al 2008), alfalfa leaf protein (Xie et al 




soymilk-kefir (Liu et al 2005), medicinal mushroom (Wachtel et al 2004), casein (Suetsuna et al 
2000), and buckwheat protein (Tang et al 2009). A long list of bioactive peptides with potential 
anticancer activity have been identified, isolated from enkephalin analogues (Daiichi and 
Yakuhin 1985; Scholar et al 1987), papaver somniferum pollen (Xu and Jin, 1998), 
antineoplastic protein (Ridge and Sloane 1996; Sloane 2002), and soy protein (Hernandez et al 
2009).  
Rice Bran as a Source of Bioactive Compounds 
Rice bran 
         Rice (Oryza sativa) is one of the most important staple foods. It feeds more than half of the 
population around the world, especially in 
Asia, Africa, and Latin America. The 
demand for rice keeps increasing because 
of the steadily growing world population 
(Wang and Li 2004). In the United States, 
the production of raw rice in year 2013 
was 265.9 million cwt with 130.1 million 
cwt of that was produced in the state of 
Arkansas (National Agricultural Statistics 
2013). The structure of rice kernel is 
illustrated Figure 1 (Lasztity 1996). Rice 
bran is the hard outeraleurone layer of the brown rice kernel. During the whiting process, which 
applies friction to the grain surface, the bran is removed from the kernel and usually accounts for 
(Lasztity 1996) 








about 10% of raw rice weight. In Arkansas, nearly 13.1 million cwt of rice bran is produced each 
year (National Agricultural Statistics 2013). 
Nutraceuticals from rice bran 
          Traditionally, rice bran is used as livestock feed supplement because of its high content of 
protein (12-15%), lipids (23%), and dietary fiber (27%) (Susan and Priscilla 2009). It also has 
been used as a natural oil extraction source in the food industry (Iqbal et al 2005).  In terms of 
human nutrition, rice bran has drawn attention recently due to its potential health promoting 
properties. It contains high quality dietary fiber (cellulose, hemi-cellulose, pectin and lignin), 
which is proven to be effective in lowering the cholesterol in plasma, decreasing the incidence of 
obesity and diabetes, and preventing physical disorers associated with the intestinal system and 
coronary heart disease (Wiboonsirikul et al 2008). Other functional compounds include some 
well-known antioxidants such as polyphenolics (phenolic acids and flavonoids), α-tocopherols 
(vitamin E), tocotrienols, and oryzanols (Nam et al 2005; Xu et al 2001). Thus, rice bran is 
considered an inexpensive food ingredient with potential nutraceutical properties (Saunders et al 
1990).  
Rice Bran Protein, Hydrolysates & Peptides  
         Protein is one of the major components in rice bran comprising 12-15% of the total weight. 
Rice bran protein contains albumin, globulin, glutelin, and prolamin with percentages of 37%, 
36%, 22%, and 5%, respectively (Tang 2002; Wiboonsirikul 2008). Rice bran protein has unique 
nutritional value compared to all the cereal bran derived proteins due to: (1) a high protein 
digestibility of more than 90%; (2) the highest content of lysine compared with other cereal bran 
proteins (Juliano et al 1985); (3) a high protein effici ncy ratio (PER) of 2.0 to 2.5 compared 




suitable infant food ingredient and would add variety in protein sources for children with food 
allergies (Burks and Helm 1994).  
Although the high content of proteins present in rice bran, proteins are bound extensively to 
phytic acid (1.7%) and fiber (12%), leading to difficulty in proteins’ separation and extraction 
using traditional solvents such as alkali, acid, salt, and alcohol, which results in low protein 
extraction yeilds. Thus, proteases have been used to nhance the solubility of rice bran proteins. 
Hamada (1999) reported that the protein extraction yield increased significantly after proper 
proteolysis with a degree of protein hydrolysis (DH) of 10%. Direct enzymatic hydrolysis has 
been applied to rice bran to produce a wide range of hydrolysates and peptides (Deslie et al 
1988).  
             In recent years, the discoveries of novel hydrolysates and peptides from rice bran protein 
have received great attention. Those bioactive hydrol sates and peptides have proven specific 
anti-disease activities such as anti-oxidative, anti-mutagenic, and anti-carcinogenic properties 
(Adebiyi et al 2009; Renuka and Arumughan 2007; Chanput et al 2009; Kannan 2010).In 
Hettiarachchy’s research program, rice bran hydrolysates were prepared by direct hydrolysis of 
heat stabilized de-fatted rice bran (HDRB). The peptid s were separated and purified.A novel 
pentapeptide, with the sequence Glu-Gln-Arg-Pro-Arg was identified with inhibitory activities 
against the proliferation of MCF-7 and MDA-MB-231 human breast cancer cell lines 
(Hettiarachchy 2013; Kannan 2010). However, the mechanistic action of this peptide on breast 
cancer cells needs investigation.   
Cancer 
            Cancer is one of the leading causes for gl bal mortality in both men and women 




cancer with the estimated deaths of 5.8 million (American Cancer Society 2013). It is estimated 
that deaths from cancer in 2015 and 2030 will increase to 9 million and 11.4 million, respectively 
(Word Health Organization 2013). Cancer, which accounts for nearly 1 in every 4 deaths, is the 
second leading cause of death in the U.S (American Cancer Society 2013). 
              Cancer is a group of diseases characterized by uncontrolled growth and spread of 
abnormal cells. Cancer cells produce growth signals themselves, ignore cell death signals, 
replicate without limits, and invade normal tissues through basement membranes and capillary 
walls (Bhutia et al 2008). In addition, tumor cells and tumor-infiltrating host cells can exert 
immunosuppressive effects to invalidate the immune system (Bhutia 2008). If the spread is not 
controlled, it can result in death. Genetic and epig netic factors contribute to the initiation of 
cancer in a normal cell. Those factors include both external factors (tobacco, infectious 
organisms, chemicals, and radiation) and internal factors (inherited mutations, hormones, 
immune conditions, and mutations that occur from metabolism). These causal factors may act 
together or in sequence to initiate or promote carcinogenesis. Ten or more years often pass 
between exposure to external factors and detectable c ncer (American Cancer Society 2013).  
Generally, traditional cancer therapies include surgery, radiation, hormone therapy, 
chemotherapy, biological therapy, and targeted therapy. However, those therapies are expensive 
and usually kill normal cells at the same time, causing side effects such as nausea, vomiting, loss 
of appetite, fever, and fatigue (Wu et al 2006). Therefore, there is an increasing need for further 
research in this area and for the pharmaceutical industry to develop more effective and less toxic 
drugs. In addition, there is a growing interest in he identification and characterization of natural 





Breast Cancer & Bioactive Peptide 
Breast cancer 
           Breast cancer is one of the leading causes of cancer related deaths and illnesses in the 
United States. In year 2013, 39,620 estimated deaths from breast cancer (females) were reported 
according to the Cancer Facts & Figures (2013). Approximately one-third of women with breast 
cancer develop metastases and ultimately die from the disease.  
            Chemotherapy, radiation therapy, and immunotherapy all rely heavily on apoptosis to kill 
breast cancer cells. However, cells can subsequently survive and gain resistance to these 
treatments leading to a more aggressive cell variant with an inclination to metastasize despite 
initially responding to the therapy (Simstein et al 2003). This chemo-resistance often results in 
the progression of breast cancers with hormone-independent, invasive, metastatic, anti-estrogen-
resistant phenotype characteristics. The underlying mechanism of chemotherapy-resistant cancer 
cells is still unknown (Campbell et al 2001).  
Cancer cell lines as in vitro models for cancer study 
 Diverse models are used for cancer studies including primary tumours, paraffin-
embedded samples, cancer cell lines,xenografts, tumor primary cell cultures (Louzada et al 2012; 
Vergo-Gogola et al 2007; van Staveren et al 2009). Due to the difficulties of animal research 
including ethical concerns, cost, maintenance and relative inefficiency, genetic and DNA 
analysis and drug testing in cell culture system has been encouraged as alternative method for the 
study of disease. Cell line model is easy to manipulate and characterize at molecular level (van 
Staveren et al 2009). It has various advantages includi g easily to be handled, cultured as an 
unlimited self-replicating source in almost infinite quantities, research data could be highly 




the characteristics of cell lines is indispensible for studyingmechanistic cellular pathways 
anddisclosing critical genes involved in various dieases. 
The use of the appropriate in vitro model in cancer research is crucial for the 
investigation of genetic, epigenetic and cellular pthways.The model are also used for studying 
proliferation deregulation, apoptosis and cancer progression anddefining potential molecular 
markers and characterization of cancer therapeutics (Louzada et al 2007; Vergo-Gogola et al 
2007; van Staveren et al 2009; Nakatsu et al 2005; Kao et al 2009). Cancer cell lines have been 
widely used for above research purposes.Their charaterization shows that they are an excellent 
tool in the genetic approach for studying of the biological mechanisms involved in cancer 
(Louzada et al 2007). The use of the cell model for testing and development of new anticancer 
drugs andtherapiesis needed (Gazdar et al 2010;Pfragner et al 2009). 
Human breast cancer cell lines: MCF-7 and MDA-MB-231 
 MCF-7, named after the place where it was first derived:Michigan Cancer Foundation-7, 
is a well-studied cell line that was first isolated in 1970 from the pleural effusion of a 69-year old
Caucasian woman (Burdall et al 2003). Currently, MCF-7 is the most commonly used breast 
cancer cell line in the world. MCF-7 cells are usefl for in vitro breast cancer studies because the 
cell line has retained several ideal characteristics particular to the mammary epithelium (Holiday 
and Speirs 2011). These characteristics include the ability to process estrogen via estrogen 
receptors in the cell cytoplasm, which makes the MCF-7 cell line an estrogen receptor (ER) 
positive control cell line. From the cell culture aspect, MCF-7 is easy to culture and is capable of 
forming the epithelial-like growsas monolayer in the flask. The growth of MCF-7 can be 
inhibited by inducing tumor necrosis factor alpha (TNF-α) and anti-estrogens, which makes 




Another commonly used cell line for in vitro human breast cancer research is MDA-MB-
231. This cell linewas obtained from a patient in 1973 at M. D. Anderson Cancer Center 
(Holiday and Speirs 2011). One of the majordifferences between MCF-7 and MDA-MB-231 
cells is that the MDA-MB-231 cell line has an invasive phenotype, which could be used as a 
model for study of breast cancer in metastasis status (Wang 2009). It has anepithelial-like 
morphology and appears phenotypically as spindle shaped cells (Sorlie et al 2009). Compared to 
MCF-7 cells, MDA-MB-231 cells grow much faster and are more resistant to drug therapies. For 
instance, reseveratrol is a potential chemopreventative gent in fighting human cancers. However, 
reseveratrol can only induce apoptosis in MCF-7 cellsbut not in MDA-MB-231 (Pozo-Guisado et 
al 2002).  
Bioactive peptide 
              Recently, studies on both the preparation of small molecular therapeutics (like peptides) 
and their mechanisms of action in treating, preventing, and management of various diseases have 
drawn the attention of the scientific community. Among those peptides, food derived peptides 
with potential antitumor activity have drawn increasing attention and several of them have 
moved forward to clinical trials. In comparison with other chemotherapies, bioactive peptides 
possess the advantages of high affinity, strong tare  cells specificity, low toxicity, and high 
modification feasibility (Michael and Erkki 2004).  
Potential sources of anticancer peptides are found in both animal and plant foods. 
Soybean is the primary plant source of anti-tumor peptides. Kim et al (2000) concluded that 
soybean protein hydrolysates showed inhibition abilities on cancer cell growth. The anti-
proliferation abilities of soybean hydrolysates against cancer cells were also reported by Kops et 




also studied. The most well known soybean-derived pptide is called lunasin, which is a linker 
peptide with 43 amino acids that has shown outstanding carcinogenic suppressing capacities in 
both in vitro and in vivo models.  
Apart from soybean, two other anticancer peptides have also been identified, purified, 
and characterized from wheat (Matsui et al 1999) and rice bran (Hettiarachchy 2013; Kannan et 
al 2010). Kannan et al (2009) prepared rice bran hydrol sates from heat stabilized de-fatted rice 
bran (HDRB) using Alcalase. The hydrolysates were then treated with a stimulated 
gastrointestinal (GI) juice and separated into fractions with different molecular weights (>50, 10-
50, 5-10, and <5 kDa) using ultrafiltration. Those fractions were evaluated for multiple-site 
(human breast, colon, and liver cancer cell lines) anticancer activities and a <5 kDa fraction 
showed 70-80% growth inhibition activity on human breast cancer cells (MCF-7). After isolation 
and purification, a novel pentapeptide (EQRPR: Glu-n Arg-Pro-Arg) was identified and 
showed inhibitory activities onMCF-7 human breast cancer cell lines (Kannan et al 2010). The 
structure of pentapeptide is shown as Figure II.  
As for animal food sources, 
milk and fermented milk products are 
most intensively studied and are 
considered the major source of novel 
anticancer hydrolysates and peptides 
(Ganjam et al 1997; Manso et al 2002; 
Takeda et al 2004; Meisel 2004). 
Other well-studied animal food peptides sources include fish (Lee et al 2004; Picot et al 2006), 
egg (Pellegrini et al 2004; Davalos et al 2004), and whey protein (Papenburg et al 1990). Despite 




the advances in discovering novel bioactive peptides, future research should also focus on 
improving the efficiency of the peptide targets on cancer cells by delivering them at a desired 
location with appropriate dosage. The biological mechanism of each tumor-targeting peptide 
against specific cancer cell lines is neededfor further research before being used as therapeutics 
in humans. 
 
Biomarkers & Possible Mechanism of Bioactive Peptide Against Breast Cancer 
Apoptosis 
Generally, physiological and pathological stimuli may trigger a process of genetically 
programmed cells death (PCD), otherwise known as apoptosis. The morphological changes 
during the apoptosis of cells include double-stranded DNA fragmentation, condensation of 
chromatin, cellular atrophy, and protrusion of the c ll membrane (Earnshaw et al 1999).  
Apoptosis plays a critical role in the development of a variety of human diseases including 
cancer, immune system diseases, and neurodegenerative disorders. Apoptosis is a multi-step, 
multi-path cell-death program that is inherent in every cell of the body. In the process of 
tumorgenesis, the ratio of proliferated cell and apoptotic cells is altered and uncontrolled, 
followed by the invasion of tumor cells with metastatic potential (Olopade et al 1997). 
In cancer treatment, anti-cancer agents such as chemot rapy and irradiation kills target 
cells primarily by inducing apoptosis. The steps are: 1) initiation of apoptosis; 2) activation of 
the caspases by a signal transduction cascade; and 3) proteolytic cleavage of cellular components. 
The general apoptosis pathway is initiated by various stimuli such as heat shock, viruses, toxic 
insults, cytokines, hormones, DNA damage, and growth factor deprivation (Earnshaw et al 1999). 
During the early stage of caspase cascade initiation which will lead to the final death of cell, 
 
apoptosis is mediated by various downstream signaling factors including Bcl
inhibitor of apoptosis proteins (IAP), nuclear factor
protein kinase (MAPK) family (Simstein 
including the death receptor-dependent (Extrinsic) pathway and
(Intrinsic) pathway involve the activation of caspae
Yuan et al 1998). The caspase-
substrates including DNAse which lead 
fragmentation in apoptotic cells (Degen et al 2000; Stroh and Schulze et al 1998; Casciola et al 
1995). Caspase-8 is activated through 
death receptors. Caspase-9 is involved in 
mitochondrial cytochrome c leakage (Kumar 1999). 
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           Caspases, a group of cysteine-dependent aspartate-directed proteases, plays the most 
important role in controlling cell apoptosis. They act as proenzymes consisting of a pro-domain 
and a catalytic protease domain. Caspases are subcla sified as initiator caspases (e.g., caspase-8, 
-9, -10, and -12) and effector caspases (e.g., caspase-3, -6, and -7). The upstream initiator 
caspases activate the downstream effector caspases, which cleave other cellular proteins and lead 
to apoptosis (Okun et al 2008).  
           The caspase cascade is the primary feature of cell apoptosis. The caspase cascade may be 
activated by two pathways: the intrinsic pathway and the extrinsic pathway (Yamasaki-
Miyamoto et al 2009). In the early stage of the intrinsic pathway, the mitochondria serve as the 
primary target for tumor necrosis factor (TNF)-induced cytotoxicity, which leads to the release 
of cytochrome C, followed by the activation of adaptor protein Apaf-1. The Apaf-1 activates the 
initiator caspase (procaspase-9), resulting in the activation of downstream effector caspases. In 
the extrinsic pathway, apoptosis is induced by a mitochondria-independent way. The death 
receptor proteins such as Fas, are activated, followed by cleavage of procaspase-8, and the 
initiation of the caspase cascade (Kim et al 2002). 
            Although the observation of the caspase cascade is considered the most important 
benchmark for the characterization of the potential efficiency of certain cancer treatment, there 
are differences in caspase expression between various cancer cell lines. The most unique feature 
of the MCF-7 breast cancer cell line is that caspase-3 is not expressed, due to the deletion of 
casp-3 gene (Kurokawa et al 1999). Liang et al (2002) reported that a sequential expression of 
caspases-9, -7, and -6 was observed, without the activation of caspase-3. Janicke et al (1998) 




apoptotic cells, such as DNA fragmentation, despite the fact that caspases-3 is not required for 
TNF-induced apoptosis. However, Yang et al (2001) found that the presence of caspase-3 
increased MCF-7’s apoptotic sensitivity. The study of pentapeptide-induced caspase cascade in 
apoptotic human breast cancer cells is the first step to understand its mechanistic potency in 
human breast cancer. 
Biomarkers 
As an important biological indicator of cancer status and progression of the physiological 
state of the cell at a specific time, biomarkers (Bcl-2 family proteins, TNF-α, Fas, and Cox-2) 
represent powerful tools for monitoring the course of cancer and gauging the efficacy and safety 
of novel therapeutic agents. 
            The Bcl-2 family proteins are considered vital control points of apoptosis due to the 
regulation of the release of cytochrome C and the activation of caspase-9. The subfamilies of 
Bcl-2 proteins include anti-apoptotic proteins (Bcl-2, Bcl-XL, Mcl-1, Bfl- 1/A1, Bcl-W, Bcl-G) 
and pro-apoptotic proteins (Bax, Bak, Bok, Bad, Bid, Bik, Bim, Bcl-XS, Krk, Mtd, Nip3, Noxa, 
Bcl-B) (Danial 2007). Bax-like death factors such as Bax, Bak, and Bok/Mtd induce apoptosis 
by building channels on membranes for cytochrome C release. There are several possible 
theories to explain the mechanism of proapoptotic protein-induced cytochrome C release: 1) the 
formation of a new channel (Schlesinger et al 1997); 2) the enlargement of existing transition 
pore permeability (Tsujimoto and Shimizu 2000); and 3) the formation of supramolecular 
openings (Zamzami and Kroemer 2001). Anti-apoptotic proteins, generally classified as Bcl-2-
like survival factors include Bcl-2, Bcl-xL, Bcl-w, A1/Bfl-1, Boo/Diva/Bcl-B and Mcl-1. These 
anti-apoptotic proteins are located on the outer mitochondrial membrane and protect the cells by 




family proteins affect cellular sensitivity to apopt sis and the ratio of pro-apoptotic proteins and 
anti-apoptotic proteins determines the fate of cells. The Bcl-2 proteins also interact with caspases 
in a mitochondrial-independent pathway. For example, th  caspase adapter Apaf-1 can be 
inactivated by binding with the anti-apoptotic protein Bcl-XL (Gross et al 1999). Many factors 
affect the levels of individual Bcl-2 proteins, such as the lineage of the cell, the activation of 
transcription factors, nonendogenous chemicals, and estrogen responsiveness.  
              TNF-α is a naturally occurring cytokine secreted by cells of the immune system and 
other systems (Feuerstein et al 1994). Although TNF-α is cytotoxic to some tumor cells, it is 
rarely cytotoxic to normal cells. This unique property has led to numerous studies of TNF as a 
chemotherapeutic agent and apoptosis-inducing agent (Erika et al 2006). TNF can activate both 
apoptotic pathways and survival pathways inside the cell. TNF-α has two receptors, p55 (TNFR1) 
and p75 (TNFR2), with most apoptotic pathways mediat  through p55 (Story et al 1998). 
Although p55 expression is necessary for TNF to produce apoptosis, it is not sufficient by itself. 
Many death and survival genes, which are regulated by extracellular factors, are involved in 
apoptosis (Simstein et al 2003).  
             Fas, also named Apo-1 or CD95, is a member of the TNF and nerve growth factor (NGF) 
receptor (Keane et al 1996). Fas is located on the cell surface and is activated by its ligand (Fas L) 
binding. Fas then forms the death-inducing signaling complex (DISC), which finally leads to the 
activation of effector caspases resulting in apoptosis in cells (Chopin et al 2002; Chen and Lin 
2004). Studies have reported that anticancer drugs activate apoptosis in breast cancer cells by 
inducing the expression of death receptor ligands, such as Fas (Fulda et al 1998). In recent years, 
there is a growing interest in studying chemotherapi s by targeting specific death receptors such 




mechanism of death receptor induced apoptosis is based on the direct activation of caspase 
machinery (Ashkenazi and Dixit 1998). Therefore, it is necessary to evaluate the expression of 
Fas and FasL levels in apoptotic human breast cancer cell lines induced by the pentapeptide.  
           Cyclooxygenase (COX), generated from free arachidonic acid, is an important enzyme in 
charge of formation of prostaglandin (PG) H2 from arachidonic acid and is expressed in the 
prostanoid biosynthetic pathway. It has received considerable attention due to its multiple roles 
in human cancer development, including stimulation f cell growth, angiogenesis, cell 
invasiveness, and increasing the production of mutagens. On the other hand, COX-2 also inhibits 
apoptosis and suppresses the immune system.  There is clear evidence that the overexpression of 
COX-2 enhances the production of several PGs that regulate various physiological processes 
(Brown and DuBois 2005). The effect of COX-2 on cell growth results from the increased 
production of PGE2 and PGF2, which contributes to cell proliferation (Bandopadhyay et al 1987). 
Meanwhile, on the side of apoptosis, there is sufficient evidence that COX-2 suppresses 
apoptosis by changing the cellular levels of anti-apoptotic and pro-apoptotic proteins (Devendra 
et al 2004). For example, COX-2 stimulates the activ tion of Akt, which is responsible for 
inactivation of pro-apoptotic proteins (Lin et al 2001). Further along in cancer development, 
COX-2 also stimulates the invasion of cancerous cells to other tissues, which increases cancer 
metastasis. In addition, PGE2 induces inverse effects on the activity of natural killer cells such as 
T and B cells. Evaluation of COX-2 levels in pentapeptide treated human breast cancer cells may 
improve our understanding of the underlying mechanism of pentapeptide induced human breast 
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Anti-proliferative effect of pentapeptide on human breast cancer cell models (MCF-7 and 
MDA-MB-231) 
Ruiqi Li, Navam Hettiarachchy, Mahendran Mahadevan 
Abstract 
Bioactive peptides derived from food sources with anti-proliferative properties against cancer 
have drawn more attention in recent years. Studies have focused on the characterization of 
peptides from natural sources that contribute specific health benefits. A pentapeptide derived 
from rice bran has shown anti-proliferative properties against human breast cancer cell lines 
(MCF-7 and MDA-MB-231). The objective of this study was to investigate the anti-proliferative 
activities of this pentapeptide on growth of breast cancer cell models (MCF-7 and MDA-MB-
231). The MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt] assay was used to evaluate the growth inhibition activities of the 
pentapeptide in a dose- (10, 50, 100, 200, 400, 500and 1000 µg/mL) and time-dependent 
manner (24, 48, 72, and 96 h). The trypan blue exclusion assay was used to determine the cell 
viabilities of both breast cancer cell lines and noncancerous breast cells (HMEC) after 
pentapeptide treatment. Decreases in growth of MCF-7 and MDA-MB-231 cells were observed 
after treatment with the pentapeptide. The maximum inhibitory activities were found on MCF-7 
(90.9%) and MDA-MB-231 (87.0%) after incubating with the pentapeptide for 72 and 96 hrs, 
respectively. The results suggested that the pentapp ide inhibits the growth of human breast 
cancer cell lines in a dose- and time-dependent manner and has no effects on the growth of 






Rice (Oryza sativa) is considered the primary staple food for more than half of the 
population of the world. In the United States, the state of Arkansas ranks first in the production 
of rough rice (125.9 million cwt), which accounted for nearly 47.9% of national total production 
(262.5 million cwt) in 2013(National Agricultural Statistics Service 2013). Rice bran is the hard 
outside aleurone layer of the brown rice kernel. Bran is removed from the kernel by friction 
during the production of white rice and it accounts for about 10% of rough rice (Parrado et al 
2006).  
 Traditionally, rice bran is underutilized as a livestock feed supplement and natural oil 
extraction source due to its high content of protein (12-15%), lipids (23%), and dietary fiber 
(27%) (Susan and Priscilla 2009). It contains a high content of dietary fiber and antioxidants 
such as polyphenolics (phenolic acids and flavonoids), α-tocopherols (vitamin E), tocotrienols, 
and oryzanols. These compounds have proven their bioactivities including lowering the 
cholesterol, decreasing the incidence of obesity, diabetes, intestinal system disorders, and 
coronary heart diseases.  
 Commercially, the rice bran is heat stabilized to prevent hydrolysis and oil oxidation 
during extraction. The resulting defatted (removal of 15-20% oil) by-product is called heat-
stabilized defatted rice bran (HDRB).HDRB contains approximately 18.5-20.9% protein, 25.2-
25.6% total fiber, 15.3-16.8% starch, 1.5-2.0% lipid, 2.0-2.5% total phenolics, 1.73-2.28% phytic 
acid, 10.5-12.0% water, and 9.0-10.4% ash (Hettiarachchy 2009).HDRB contains increased 
percentages of fiber (35-48%) that can be used in fiber-dense food products. It also contains 
higher protein content (15-20%) that can be extracted with dilute alkali and enzyme treatment to 




 As a protein rich plant source, rice bran protein derived hydrolysates and peptides have 
received considerable attention as potential anti-oxidative, anti-mutagenic, and anti-carcinogenic 
agents (Adebiyi et al 2009; Renuka and Arumughan 2007; Chanput et al 2009; Kannan et al 
2010). Enzymatic hydrolysis by pancreatic enzymes, especially trypsin, is considered the most 
effective method to produce value-added bioactive peptides (Möller et al 2008). In the 
preparation of bioactive hydrolysates and of peptides erived from rice bran, direct enzymatic 
hydrolysis has been widely used due to its advantage in breaking down the extensive bonding 
between proteins and phytic acid (1.7%) and fiber (12%).  
 Cancer is one of the leading causes for global mortality in both men and women 
(Kaufman and Earnshaw 2000). Breast cancer is one of the leading causes of cancer related 
deaths and illnesses in the United States. 39,620 estimated deaths for breast cancer (females) 
were reported in 2013 (Cancer Facts & Figures 2013). Generally, traditional cancer therapies 
include surgery, radiation, hormone therapy, chemotherapy, biological therapy, and targeted 
therapy. However, those therapies result in side effects such as nausea, vomiting, loss of appetite, 
fever, and fatigue (Wu et al 2006). In addition, these treatments may select cancer cells that can 
subsequently survive, which lead to a more aggressiv  cell variant with an inclination to 
metastasize (Simstein et al 2003).  
              Kannan et al (2009) prepared rice bran hydrolysates from HDRB by hydrolysis using 
Alcalase. The hydrolysates were then treated with stimulated gastrointestinal (GI) juice and 
separated into fractions based on their molecular weight (>50, 10-50, 5-10, and <5 kDa) using 
ultrafiltration. Those fractions were evaluated formultiple-site (human breast, colon, and liver 
cancer cell lines) anticancer activities and the <5 kDa fraction showed 70-80% growth inhibition 




pentapeptide with a sequence Glu-Gln-Arg-Pro-Arg was identified and showed inhibitory 
activities against the proliferation of MCF-7 human breast cancer cell lines (Kannan et al 2010).                          
 The objective of this study was to determine the anti-proliferative effect of the 
pentapeptide on human breast cancer cell models (MCF-7 and MDA-MB-231). The growth 
inhibition properties of pentapeptide against breast c ncer cells was evaluated by MTS assay and 
Trypan blue assayin a time- and dosage-dependent manner. 
 
Materials and Methods 
Materals. Pentapeptide (amino acids sequence: EQRPR: Glu-Gln-Arg-Pro-Arg) was purchased 
from Biomatik LLC. (Wilmington, Delaware, USA). Human breast cancer cell lines (MCF-7: 
ATCC HTB-22TM and MDA-MB-231: ATCC HTB-26TM) and normal human mammary 
epithelial cells (HMEC: ATCC PCS-600-010TM) were purchased from ATCC (American Type 
Culture Collection). The Bovine Pituitary Extract (BPE), Eagle's Minimum Essential Medium, 
serum free medium, fetal bovine serum (FBS), insuli, trypan blue powder, and trypsin-EDTA 
solution were purchased from Sigma (MO, USA). The MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt]one solution kit was 
obtained from Promega Corporation (Madison, WI, USA). 
Methods. 
Cell culture. The human breast cancer cell lines (MCF-7 and MDA-MB 231) were selected as 
breast cancer cell models in this research. MCF-7 was derived in the Michigan Cancer 
Foundation-7 in 1973 from pleural effusion in a breast cancer patient. MCF-7 cells are useful for 
in vitro breast cancer studies due to their capacity to process estrogen via estrogen receptors in 




cell line. The MDA-MB-231 breast cancer cell line was obtained from a patient in 1973 at M. D. 
Anderson Cancer Center. MDA-MB-231 breast cancer cells have an epithelial-like morphology, 
which appear phenotypically as spindle shaped cells. The difference between the two cell lines is 
that MCF-7 is an ER-positive breast cancer line derived from an in situ carcinoma, meaning that 
the cancerous cells had not yet invaded surrounding tissues; however, the MDA-MB-231 is an 
ER-negative breast cancer line derived from a metastatic carcinoma. Selection of both cell lines 
helps in better illustrating and understanding the m chanism of pentapeptide-induced growth 
inhibition on human breast cancer. For evaluating the growth effects of normal human breast 
cells caused by pentapeptide, the HMEC (Human Mammary Epithelial Cells) which were 
derived from normal adult mammary glands, was select d. 
 For cell culture method, the human breast cancer cell lines (MCF-7 and MDA-MB-231) 
were grown in the recommend conditions (ATCC, Manassas, VA, USA). The MCF-7 cells were 
cultured in a 75 cm2 flask with Eagle's Minimum Essential Medium supplemented with 
0.01mg/mL bovine insulin and 10% FBS. The HMEC was cultured with serum-free medium 
supplied with insulin (5.0 µg/mL) and BPE (70 µg/mL). Then, the cells were grown in a 
humidified 5% CO2 incubator at 37°C for about 7 days and reached 80 to 9 % of fully confluent 
(approximately 5 x 106 cells) before cells were collected for further assays. The MDA-MB-231 
cells were cultured in a canted neck 75 cm2 flask (to maintain the inside atmosphere in the flask) 
with Leibovitz's L-15 Medium including 10% FBS and incubated at 37°C in an incubator with 
95% relative humidity. 
 
Cell growth inhibition assay (MTS).The cytotoxic effects of pentapeptide on the breast c ncer 




were evaluated by the MTS assay (Kannan et al 2010). MTS assay is a colorimetric method for 
determining the number of viable cells after a certain reatment. The principle of this assay is that 
the MTS are reduced to formazans by the cytochrome systems (in the presence of Lactate 
Dehydrogenase) of viable cells, and the blue color developed is a direct measure (at 490 nm) of 
the viability of the cells. The amount of colored product formed is proportional to the number of 
living cells. In this study, the cell viabilities of human breast cancer cell lines and HMEC were 
determined using MTS assay after pentapeptide treatment. Cells (MCF-7, MDA-MB-231, and 
HMEC) were cultured using respective methods described above and collected from a 75 cm2 
flask using trypsin-EDTA digestion. The cells were re-suspended in the media and the cell 
densities were determined using a hemocytometer. Then, cells were diluted with the media 
(Eagle's Minimum Essential Medium and Serum Free Medium) to reach a density of 2.5 x 
104cells/mL and transferred into a 96-well plate with 200 µL per well. The cells (5 x 103 
cells/well) were allowed to attach for 24 hr before removing the spent media. The pentapeptide 
was dissolved using media at various concentrations (10, 50, 100, 200, 400, 500, and 1000 
µg/mL), media alone (negative control), and genistein at 400 µg/mL (positive control) were 
added to the respective well with 200 µL of final vo ume and incubated for various time periods 
(24, 48, 72, and 96 h). All treatments (including negative and positive controls) were conducted 
in triplicates within three wells in each 96-well pate. Genistein was selected as positive control 
because it is well-recognized as an anti-breast cancer agent and it is very effective at an 
optimized concentration of 400µg/mL (Hsieh et al 1998; Kannan et al 2008; Kannan et al 2010). 
The MTS one solution reagent was added to each well (40 µL/well) and the plate was incubated 
in the dark (to prevent discoloration of MTS reagent) at 37°C for 1 hr to allow color 




after adding 10% SDS to each well for reaction termination. The cytotoxic effect of the 
pentapeptide was expressed as a relative percentage of cell survival rate calculated as follows:  
Relative survival rate (%) = A490Sample ×100 / A490Negative control 
A490Negative control: Absorbance at 490 nm of cells cultured with media alone; A490Sample: 
Absorbance at 490 nm of cells treated with pentapeptid  or genistein at various conditions. 
 
Cell viability assay (Trypan blue dye exclusion). Trypan blue assay is a dye exclusion method 
that determines the number of dead/live cells by using trypan blue dye to stain dead cells in blue 
and counted under a microscope (VWR® Inverted Micros ope) using a hemocytometer. Since 
live cells with intact cell membranes cannot be stained due to the membrane selectivity of 
compounds (Trypan blue dye does not penetrate membranes), the live cells could be also counted 
using a hemocytometer. In this study, cells (MCF-7, MDA-MB-231, and HMEC) were cultured 
as monolayer and grown for 3 days on 24-well flat-bottom plates. The pentapeptide at various 
concentrations (10, 50, 100, 200, 400, 500, 1000 µg/mL) in media were added to each well and 
treated for various times (24, 48, 72, and 96 hr). Genistein (400 µg/ml) in media and media alone 
were used as positive and negative controls, respectively. The spent media was removed by 
aspiration and cells were trypsinized from the plates using trypsin-EDTA solution to detach cells 
from the cell culture substratum. The trypsinized clls were transferred into a 15 mL centrifuge 
tube and re-suspended using 10 mL fresh media. Then, 100 µL of cell suspension was stained by 
100 µL of0.5% Trypan blue dye.  
 
Data Analysis. All the treatments in MTS and Trypan blue assay were conducted in triplicates 




cytotoxic effects of pentapeptide on human breast cncer cell lines and normal breast cells were 
analyzed by analysis of variance (ANOVA) using the Statistical Analysis System (SAS 9.2 2000, 
SAS Institute Inc., Cary, N.C., U.S.A.). The Fisher’s protected least significant difference (LSD) 
test was conducted to separate the means at P ≤ 0.05.  
 
Results and Discussion 
To determine the growth inhibitions of the pentapeptide on human breast cancer cell lines, 
the MTS assay and Trypan blue assay were used to evaluate the anti-proliferative activities after 
pentapeptide (50, 100, 200, 400, 500, and 1000 µg/mL) treatment for various times (24, 48, 72, 
and 96 h). The Figure 1.1and 1.2 shows that pentapep ide decreased the survival of MCF-7 and 
MDA-MB-231 cells in a time-dependent manner compared to negative controls (cells cultured 
using media alone). The maximum inhibitory activities were found on MCF-7 (90.9%) and 
MDA-MB-231 (87.0%) after incubation with pentapeptide for 96 hrs. A relatively lower growth 
reduction on MDA-MB-231 cells suggested it was more resistant to pentapeptide treatment than 
MCF-7 cells. No significant (p > 0.05) decreases in survival of pentapeptide treated HMEC 
(normal breast cell line) were observed, which suggested that the pentapeptide has no cytotoxic 
effect on normal human breast cells (Figure 1.3).    
The Figure 1.4 shows that the pentapeptide at various c ncentrations inhibited the growth 
of both cell lines in a dose-dependent pattern. The maximum growth inhibitions were achieved 
after treatment with pentapeptide at the highest concentration of 1000 µg/mL on MCF-7 (90.9%) 
and MDA-MB-231 (87.0%). Significant (p < 0.05) decrases in survival of pentapeptide treated 
MCF-7 and MDA-MB-231 cells were observed compared to negative controls. The anti-




the increasing dosages of pentapeptide. There were no significant differences (p> 0.05) in growth 
inhibitions of pentapeptide at dosages of 1000 µg/mL and 500 µg/mL on MCF-7 cells. These 
results suggest that the growth inhibition activity of pentapeptide was saturated at a 
concentration of 500 µg/mL on MCF-7 cell line. The p ntapeptide had shown relatively higher 
anti-proliferative activities on MCF-7 cells at each oncentration than on MDA-MB-231 cells 
(Figure 1.4). This result could be explained by the c aracteristics of two human breast cancer 
cell lines. MDA-MB-231 is more resistant to anti-can er treatment since it is derived from a 
cancerous site that was in metastatic status (late st ge of cancer) (Awad et al 2000). Figures 1.4 
and 1.5 shows the cell viabilities of pentapeptide treated MCF-7, MDA-MB-231, and HMEC 
determined using Trypan blue assay. These results sgge ted that pentapeptide inhibits the 
growth of cancerous human breast cell lines in a time- and dose-dependent pattern while 
pentapeptide has no anti-proliferative activity on HMEC cells.  
Both results determined by MTS assay and Trypan blue assay have the similar trends 
which shown that the pentapeptide inhibits the growth of both human breast cancer cell lines, 
however, the survival (%) of cells treated with pentapeptide determined by trypan blue assay are 
relatively higher than the results evaluated by MTS assay. This difference could be explained by 
the natural of two assays. MTS assay determine the cells survival percentage by evaluating the 
levels of dehydrogenase in the mitochondria of the cells, while the Trypan blue assay 
differentiates the alive or died cells through the integrity or damage of cell membrane. It is 
highly possible that the death of breast cancer cells start from the damage of mitochondria after 
the pentapeptide treatment then gradually damage the in egrity of the cell membrane. Thus, the 





These findings show the anti-proliferative activities of pentapeptide on growth of human 
breast cancer cell lines (MCF-7 and MDA-MB-231), which signify that the rice bran derived 
pentapeptide could be a potential anti-breast cancer ag nt. Previous research has shown that the 
pentapeptide caused growth inhibitions on several cancer cell lines including Caco-2, MCF-7, 
HepG-2, and A549 (Kannan et al 2010). In this study, media alone and genistein (400 µg/mL) 
were used as negative and positive controls. Genistei  causes growth inhibition on human breast 
cancer cells via apoptosis and was used as a positive control (Fioravanti et al 1998). In this study, 
the pentapeptide results in anti-proliferative activities on MCF-7 (90.9%) and MDA-MB-231 
(87%) may also be due to apoptosis.  
In recent years, bioactive peptides are emerging as a novel alternative for anti-cancer 
drugs. They exert functions through regulated protein–protein or protein–DNA interactions 
(Borghouts et al 2005). The bio-activities of functional peptides are based on their amino acid 
composition and sequence (Kannan et al 2010).Generally, those bio-active peptides consist of 5 
to 40 amino acids and exhibit multifunctional activities including anti-oxidative, 
immunomodulatory, ACE-inhibitory, hypocholesterolemic, anti-microbial, and anti-cancer 
activities (Meisel and FitzGerald 2003; Kim et al 2008). Studies have shown that short peptides 
with 2 to 5 amino acids were produced from natural sources and possess various biological 
activities (Saiga et al 2003; Parkash et al 2002; Nagaoka et al 2001; Suetsuna et al 2000).  
In the present study, the pentapeptide with a sequence of Glu-Gln-Arg-Pro-Arg (EQRPR) 
showed significant anti-breast cancer activities. The major advantages could be explained by the 
size and composition of amino acids. Shorter peptids (less than 10 amino acids) could 
exposethe functional groups more efficiently due to their higher solvent accessibility (Kannan et 




purified from soy protein, wheat germ, and whey protein respectively (Kim et al 2007; Korhonen 
and Pihlanto 2003; Sannier et al 2000). The Pro and Arg in the pentapeptide are thought to be 
major contributors to its anti-cancer activities. David and Ramamoorthy (2008) concluded that 
anti-microbial peptides such astritrpticin, lactoferricins, and indolicidin are rich in positively 
charged residue such as Arg. PR-39 is a linear peptide isolated from procine small intestine. It 
exerts anti-cancer activities and is rich in Arg and Pro (Agerberth et al 1991). In addition, the 
presence of proline may increase the pepetide’s accessibility to solvent due to its predominance 
in turns of a polypeptide chain. Kim et al (2008) isolated an anticancer peptide from soy protein 
with a high percentage of Pro (22%). High frequency o currences of proline residue are also 
observed in other bioactive peptides and assume to play an indispensible roleon bioactivity of the 
peptide (Andrushchenko et al 2006).  
 
Conclusion 
In summary, the results determined using MTS assay and Trypan blue assay showed that 
the pentapeptide significantly inhibited the growth of MCF-7 and MDA-MB-231 cells in a time- 
and dose-dependent manner.The cancer cell death induced by the pentapeptide may be caused by 
membrane disruption through apoptosis due to its unique amino acids composition. Additionally, 
pentapeptide has no cytotoxity effect on normal human breast cells, which suggests its potential 
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Figure 1.1. Growth inhibition effects of pentapeptide (1000 µg/mL) on human breast 
cancer cell line (MCF-7) after various incubation times (24, 48, 72, and 96 hours) 
determined using MTS assay.  
The MCF-7 cellswere cultured with media alone and genistein (400 µg/mL) are considered 
negative and positive controls, respectively. The triplicate wells in each 96-well plates were run 
in duplicates. Values are means ± standard deviations of three determinations (n=6). Values with 






































Figure 1.2. Growth inhibition effects of pentapeptide (1000 µg/mL) on human breast 
cancer cell line (MDA-MB-231) after various incubation times (24, 48, 72, 96 hours) 
determined using MTS assay.  
The MDA-MB-231 cells were cultured with media alone and genistein (400 µg/mL) are 
considered negative and positive controls, respectiv ly. The triplicate wells in each 96-well 
plates were run in duplicates. Values are means ± standard deviations of three determinations 
(n=6). Values with the same letter are not significant different (P>0.05). The standard deviations 

































Figure 1.3. Effects of pentapeptide (1000 µg/mL) on human noncancerous breast cells 
(HMEC) after various incubation times (24, 48, 72, 96 hours) determined using MTS assay.  
The MDA-MB-231 cells were cultured with media alone and genistein (400 µg/mL) are 
considered negative and positive controls, respectiv ly. The triplicate wells in each 96-well 
plates were run in duplicates. Values are means ± standard deviations of three determinations 
(n=6).  Values with the same letter are not significant different (P>0.05). The standard deviations 
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Figure 1.4. The growth inhibition effects of pentapeptide at various concentrations (10, 50, 
100, 200, 400, 500, 1000 µg/mL) on MCF-7, MDA-MB-231, andhuman noncancerous breast 
cells (HMEC) after 96 hours incubation determined using MTS assay.  
The cell lines were cultured with media alone and genistein (400 µg/mL) are negative and 
positive controls. The triplicate wells in each 96-well plates were run in duplicates. Values are 
means ± standard deviations of three determinations (n=6). Values with the same letter are not 
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Figure 1.5. Survival (%) of pentapeptide (1000 µg/mL) treated human breast cancer cell 
line (MCF-7) after various incubation times (24, 48, 72, and 96 hours) determined using 
Trypan blue assay.  
The MCF-7 cellswere cultured with genistein (400 µg/mL) and media alone are considered 
positive and negative controls, respectively. The triplicate wells in each 96-well plates were run 
in duplicates. Values are means ± standard deviations of three determinations (n=6). Values with 




































Figure 1.6. Survival (%) of pentapeptide (1000 µg/mL) treated human breast cancer cell 
line (MDA-MB-231) after various incubation times (24, 48, 72, and 96 hours) determined 
using Trypan blue assay.  
The MDA-MB-231 cells were cultured with genistein (400 µg/mL) and media alone are 
considered positive and negative controls, respectiv ly. The triplicate wells in each 96-well 
plates were run in duplicates. Values are means ± standard deviations of three determinations 
(n=6). Values with the same letter are not significant different (P>0.05). The standard deviations 




































Figure 1.7. Survival (%) of pentapeptide (1000 µg/mL) treated human noncancerous breast 
cells (HMEC) after various incubation times (24, 48, 72, and 96 hours) determined using 
Trypan blue assay.  
The HMECcells were cultured with genistein (400 µg/mL) and media alone are considered 
positive and negative controls, respectively. The triplicate wells in each 96-well plates were run 
in duplicates. Values are means ± standard deviations of three determinations (n=6).  Values with 































Figure 1.8. Survival (%) of pentapeptide treated (10, 50, 100, 200, 400, 500, 1000 µg/mL) 
MCF-7, MDA-MB-231, and HMEC cells after 96 hours incubation determined by Trypan 
blue assay.  
The cellswere cultured with genistein (400 µg/mL) and media alone are positive and negative 
controls, respectively.The triplicate wells in each 96-well plates were run in duplicates. Values 
are means ± standard deviations of three determinations (n=6). Values with the same letter are 

















































The apoptotic features of the pentapeptide treated human breast cancer cell lines (MCF-7 
and MDA-MB-231) 
Ruiqi Li, Navam Hettiarachchy, Mahendran Mahadevan 
Abstract 
Studies have focused on the characterization of peptides from natural sources that contribute 
specific health benefits. A pentapeptide derived from rice bran has shown anti-proliferative 
properties on human breast cancer cell lines (MCF-7 and MDA-MB-231). The objective of this 
study was to investigate the apoptotic features of pentapeptide-induced cell death in human 
breast cancer cell models (MCF-7 and MDA-MB-231). Morphological changes, DNA 
fragmentation, and increased caspases-3/7, -8, and -9 activities are considered hallmarks of cell 
death due to apoptosis. In this study, morphological ch nges of pentapeptide treated MCF-7 and 
MDA-MB-231 cells were observed using phase contrast microscopy (magnification: 200x). 
Apoptotic cells with fragmented DNA were observed using a TUNEL-based detection kit. The 
levels of caspases-3/7, -8, and -9 activities were d t rmined using a luminescent assay. Distinct 
morphological changes including cell floating and shrinkage, nucleic blebbing, and the display of 
granular apoptotic bodies were observed in both cell lin s after pentapeptide treatment. A typical 
pattern of fragmented DNA (significant green color over orange propidium iodide (PI) counter-
staining under confocal microscopy) was also observed. Significant (p < 0.05) high levels of 
activated caspase-3/7, -8, and -9 were also determin d in pentapeptide treated MCF-7 and MDA-
MB-231 cells. These results suggest that the pentapp ide inhibits the growth of human breast 





Apoptosis, also named programmed cell death (PCD), is a genetically regulated process 
that happens in every cell and is initiated by physiological and pathological stimuli.  In normal 
tissue, the initiation of apoptosis is triggered byvarious pro-apoptotic stimuli. Then, the 
molecular executioner machinery of apoptosis is activ ted, which induce apoptotic changes in 
the nuclei (Saraste and Pulkki 2000). After the execution of apoptosis, the features of apoptosis 
become evident and observable. These features include morphological changes, DNA 
fragmentation, and activations of caspases, and have been recognized as hallmarks of apoptosis 
(Saraste and Pulkki 2000). The morphological changes during the apoptosis of cells include 
condensation of chromatin, cellular atrophy, and bleb ing (Earnshaw et al 1999). In the process 
of tumorgenesis, the ratio of proliferated cells and poptotic cells and the machinery of apoptosis 
are altered and uncontrolled. 
              Caspases are a group of cysteine-dependent aspartate-directed proteases which play an 
important role in controlling cell apoptosis. During early stages of apoptosis, the activation of 
initiator caspases by a signal transduction cascade will lead to the cleavage of cellular 
components, which finally results in the PCD. Caspases are subclassified as initiator caspases 
(caspase-8, -9, -10, and -12) and executer caspases (caspase-3, -6, and -7). The caspase cascade 
could be activated by two pathways: the intrinsic pathway and the extrinsic pathway (Yamasaki-
Miyamoto et al 2009). In early stage of intrinsic pathway, the mitochondria serves as the primary 
target for TNF-induced cytotoxicity, which leads to the activation of adaptor protein Apaf-1, 
followed by the activation of the initiator procaspe-9. In the extrinsic pathway, apoptosis is 
induced by a mitochondria-independent sequence involvi g death receptor proteins such as Fas, 




            The observation of caspase cascade is con idered one of the most important benchmarks 
for the characterization of the efficiency of certain cancer treatment. In human breast cancer cells, 
the non-expression of caspase-3 is the most unique feature of MCF-7 cell line (Kurokawa et al 
1999). Liang et al (2002) reported that a sequential expression of caspases-9, -7, and -6 was 
observed. Thus, the study of the pentapeptide-induce  caspase cascade in apoptotic human breast 
cancer cells is the first step to reveal its underlying mechanistic potency in human breast cancer. 
Our results have shown that pentapeptide induced cell death in human breast cancer cell lines 
(MCF-7 and MDA-MB-231). However, it is still unclear whether the cell death is triggered by 
apoptosis. Hence, the objective was to study the apoptotic characteristics of pentapeptide-
induced cell death of human breast cancer cell lines. These apoptotic features including 
morphological changes, DNA fragmentation, and increased levels of activated caspase-3/7,-8, 
and -9were observed and evaluated. 
 
Materials and Methods 
Materals. Human breast cancer cell lines (MCF-7 and MDA-MB-231), Leibovitz's L-15 
Medium, and Eagle's Minimum Essential Medium were purchased from ATCC. Bovine insulin, 
fetal bovine serum (FBS), Trypan blue, and genistein were purchased from Sigma (St. Louis, 
MO, USA). Fluorometric DNA fragmentation detection kit III (F-dUTP) was obtained from 
PromoKine, Germany. Caspase assay kits for caspase-7, -8, and -9 activities were purchased 








Cell culture. In Chapter 1, the research has proven that the penta p ide showed anti-
proliferative activities on human breast cancer cell lines (MCF-7 and MDA-MB-231), while 
having no cytotoxicity on normal human breast cell line (HMEC). Thus, only the mechanisms of 
pentapeptide-induced growth inhibition on human breast cancer cell lines (MCF-7 and MDA-
MB-231) were investigated in Chapter 2 and Chapter 3. The human breast cancer cell lines 
(MCF-7 and MDA-MB-231) were cultured following steps described in Chapter 1, Methods-Cell 
culture.The MCF-7 cells were cultured in a 75 cm2 flask with Eagle's Minimum Essential 
Medium supplied with 0.01mg/mL bovine insulin and 10% FBS. Then, cells were grown in a 
humidified 5% CO2 incubator at 37°C for around 7 days and reached 80 to 90% fully confluent 
(around 5 x 106 cells) before being collected for further assays. The MDA-MB-231 cells were 
cultured in a canted neck 75 cm2 flask (for maintaining the inside atmosphere in the flask) with 
Leibovitz's L-15 Medium including 10% FBS and incubated at 37°C in a humidified incubator.  
 
Observation of morphological changes. Cells (MCF-7 and MDA-MB-231) were trypsinized 
from a 75 cm2 flask and the cells number was determined by a hemocytometer under microscopy 
(magnification: 200x). Then, the cells were transferred into a 96-well plate with a density of 
5×103 cells per well. After 24 hours incubation, the spent media was removed and cells were 
treated with pentapeptide (1000 µg/ml) and incubated for 96 hrs. Genistein (400 µg/mL) and 
media alone were used as positive and negative controls, respectively. The cellular 
morphological changes were observed using phase contrast microscopy at a magnification of 
200x(Akter et al 2012). Photos of the cells treated with pentapeptide, genistein, and media were 




media with the normal morphology were considered negative controls. The morphological 
changes of apoptotic cells include the shrinkage of cells, blebbing nuclei, and floating cells 
(Allen et al 1997).  
 
DNA fragmentation. The detection of DNA fragmentation in pentapeptide reated human breast 
cancer cells was determined by fluorometric DNA fragmentation detection kit III (F-dUTP) 
following the company protocol (PromoKine, Germany). Cells (MCF-7 and MDA-MB-231) 
were cultured following the same method described above and treated with pentapeptide for 72 
hrS. The cells cultured with media were used as controls. All the cells were fixed using 1.0% 
(w/v) paraformaldehyde in 1 x phosphate buffered saline (PBS) and ice-cold 70% (v/v) ethanol. 
Then, the cells were stained with Staining Solution supplied by the company (PromoKine, 
Germany) and treated with propidium iodide/RNase solution. The Nikon Laser-scanning 
confocal microscope (Plant Pathology at University of Arkansas) was used to detect the DNA 
fragmentations in apoptotic cells.   
 
Assay for caspases activities. The activities of caspase-3/7, -8, and -9 were determined by 
caspase-Glo®assay kit following the company protocol (Promega Corp., USA). The caspase-3/7, 
-8,and -9 kits reagents were equilibrated to room te perature before use and prepared following 
the instruction. The cells were cultured and transferred into the white-walled 96-well plate with a 
density of 5 x 103 per well and allowed to attach for 24 hours. Then, the cells were treated with 
pentapeptide (1000 µg/mL) for 72 and 96 hours. One hundred µl of Caspase-Glo® reagent was 




rpm for 30 seconds, followed by 2 hours incubation at room temperature. The luminescence of 
each sample was measured using a plate-reading luminometer. 
 
Data Analysis. All the treatments in assays were conducted in triplicates and the values were 
reported as means ± standard deviation. The levels of activated caspases in pentapeptide treated 
human breast cancer cell lines were analyzed by analysis of variance (ANOVA) using the 
Statistical Analysis System (SAS 9.2 2000, SAS Institute Inc., Cary, N.C., U.S.A.). The Fisher’s 
protected least significant difference (LSD) test was conducted to separate the means at P ≤ 0.05.  
 
Results and Discussion 
Observation of morphological changes. Generally, abnormal and unhealthy cells such as 
cancerogenic cells are removed through apoptosis (Xa et al 1999). Apoptosis could be 
recognized by several biological features including morphological changes (loss of cell volume 
and mitochondrial depolarization), DNA fragmentation, and caspases activation (Saraste and 
Pulkki 2000; Mgbonyebi et al 1999).The morphological hanges are considered one of the most 
remarkable features of apoptotic cells because cell death via apoptosis exhibits a very distinctive 
pattern (Ziegler and Groscurth 2004). Thus, the morph logical changes are the unique features of 
apoptotic cell death induced by various cell anti-proliferative agents. The prominent 
morphological changes of apoptotic cells including the change of cell shape, cells round up, and 
detached from each other. One of the major difference i  cell morphology between apoptosis and 
necrosis is that the cells undergoing apoptosis still have compact organelles while the 
cytoplasmic ultrastructure of cells undergoing necrosis significantly increases with damaged 




pentapeptide-induced cell death was caused by apoptosis, the morphological changes of 
pentapeptide-treated MCF-7 and MDA-MB-231 cells were observed using a phase contrast 
microscopy (magnification: 200) and compared with the untreated controls. After 72 hrs of 
pentapeptide (1000 µg/mL) treatment on MCF-7 and MDA-MB-231 cells, the morphological 
changes (pointed out by arrows) including cell floating,shrinkage, and nucleic blebbingwere 
observed (Figures 2.1b and 2.1d); however, the control groups without pentapeptide treatment 
shown no detectable morphological changes (Figures 2.1a and 2.1c). 
 In the current study, the pentapeptide not only induced typical morphological changes in 
MCF-7 and MDA-MB-231 cells due to apoptosis but also extensive detachment of cells from the 
cell culture plates. Post 72 hours pentapeptide treatm nt, significant amounts of detached MCF-7 
and MDA-MB-231 cells were observed compared to controls (Figure 2.1). Wen et al (1997) 
suggesting that integrins on the cell membrane are abl to interact with extracellular matrix 
(ECM) components such as fibronectin, collagen, and vitronectin and results in the detachment 
of cells from substratum. The disruption of integrin-mediated signal transduction inducing by 
disassociation of integrins with ECM compounds leads to the inactivation of focal adhesion 
kinase which detaches the cells from the culture surface and apoptotic cell death (Fukai et al 
1998). Our observations of pentapeptide treated MCF-7 and MDA-MB-231 cells suggest that 
human breast cancer cells undergo apoptosis and detach from cell culture substratum (Figure 2.1 
b and d). The pentapeptide may induce the cell death via uncoupling of integrin-mediated 
signaling and/or disruption of cell-matrix interactions (Mgbonyebi et al 1999). These 
observations agreed with previous studies that suggesting the detachment of cells and changes of 
morphology are evidence of cell death induced by apoptosis (Hossain et al 2012; Hu et al 2010; 




inducesapoptosis in cells and leads to the detachment on MDA-MB-231 cells suggesting that it 
could be a very promising in preventing/inhibiting the initiation/growth of metastatic cancer cells 
since the adhesion is crucial for cancer metastasis (Wong et al 1998). 
 
Pentapeptide Induced DNA fragmentation in MCF-7 and MDA-MB-231 Cells. In the above 
section (observation of morphological changes), our data suggest that pentapeptide induced 
MCF-7 and MDA-MB-231 cell death may be caused by apoptosis. However, both morphological 
and biochemical features must be justified to confirm that cell death has occurred via apoptosis 
(Bortner et al 1995).Wyllie and Kerr (1972; 1980) pro osed that DNA fragmentation is involved 
in cell apoptosis, showing that fragmented DNA with 180 to 220 bp lengths is observed before 
cell death. Afterwards studies and publications have proven that this form of DNA fragmentation 
is very widely observed in apoptosis of various cells and tissues under different circumstances 
(Bortner et al 1995). Thus, the degradation of internucleosomal DNA, the best-characterized 
biochemical benchmark, is evaluated in current study as the definitive apoptotic marker (Saraste 
and Pulkki 2000; Allen et al 1997). 
 The nuclear DNA is the genetic material that is crucial for producing cellular proteins; 
the cleavage of DNA into fragments represents the most severe damage to the cell (Zhang and 
Xu 2002).This process occurs after the cells are attacked by various apoptotic stimuli. The 
chromosomal DNA is cleaved by nucleases in a caspase-dependent manner. One apoptotic 
nuclease is DNase (CAD, caspase-activated DNase),which requires Ca2+ and Mg2+ and is 
inhibited by Zn2+ (Peitsch et al 1992).The initiator caspases such as caspase-8 and -9 are 
activated and subsequently activate downstream executor aspases including caspases-3, -6, and 




downstream caspases. The cleavage of CAD on DNA is responsible for the fragmented genetic 
materials, which results in the biochemical changes that characterize apoptotic cell death (Nagata 
2000).This phenomenon can be analyzed by agarose gel electrophoresis, which measures DNA 
fragmentation in nuclear extracts showing the typical “DNA-ladder” configuration. Another 
method to measure DNA fragmentation is based on the lab ling of free 3-hydroxyl ends of the 
fragmented DNA with the fluorescein-12-dUTP under the erminal deoxynucleotidyl transferase 
(TdT) catalyzing (Rosl 1992; Gavrieli et al 1992). Sgonc and Gruber (1998) also suggest that the 
TdT-mediated dUTP nick end-labeling (TUNEL)-based method is highly recommended for 
characterization of apoptotic cells, simultaneous determination of cell markers, and apoptosis. 
 In the current study, a TUNEL-based kit was used to etect the DNA fragmentation in 
pentapeptide treated apoptotic MCF-7 and MDA-MB-231 cells. The TdT catalyzes the 
fluorescein-12-dUTP incorporation located at the free 3’-hydroxyl ends of the fragmented DNA. 
Confocal microscopy was used to observe the fluorescein-labeled fragmented DNA from the 
stained apoptotic cells which showing green fluorescence at 520 nm against an orange red 
propidium iodide (PI) counter-stain (fluorescence at 620 nm). After MCF-7 and MDA-MB-231 
cells were treated with pentapeptide (1000 µg/mL) for 72 hr, the DNA fragmentation assay was 
performed and the results revealed a typical fragmented DNA pattern (Figures 2.2b and d) 
compared to negative controls (Figures 2.2a and c). This is in agreement with results by Sgonc 
and Gruber (1998), which the apoptotic cells showed a green-stained nuclei after being labeling 
by TUNEL technique. Other studies also observed fragmented DNA in various cancer cell lines 
after treatment with different anti-cancer agents including fucoidan, melatonin, ganoderma 
lucidum extract, epinecidin-1, roscovitine, and wortmannin (Yamasaki-Miyamoto et al; 2009; 




These results combined with results describing morph logical changes suggest that pentapeptide 
is able to induce human breast cancer cell death vi apoptosis.  
 
Pentapeptide induces apoptosis in human breast cancer cells (MCF-7 and MDA-MB-231) 
through the caspases-dependent pathway. To verify the role of caspases in pentapeptide-
induced growth inhibition on human breast cancer cells, the levels of caspase-3/7, -8, and -9 
were evaluated after appropriate treatments. Genistei  (400 µg/mL) was used to induce apoptosis 
in MCF-7 and MDA-MB-231 cells and was considered the positive control. Significantly 
increased (p< 0.05) levels of active caspase-3/7 fragments were d t cted in both cell lines in the 
presence of pentapeptide (1000 µg/mL) from 72 to 96 hr (Figure 2.3). MDA-MB-231 cells have 
also shown comparatively higher levels of caspase-3/7 than MCF-7. Significantly increases (p< 
0.05) in levels of activated caspase-8 and caspase-9 w re detected at 72 and 96 h after the 
pentapeptide treatment compared to the controls (MCF-7/MDA-MB-231 cultured with media). 
Pentapeptide induced significant (p< 0.05) increases in relative caspase-8 intensity in MCF-7 
(from 5.2 to 7.7 folds) and MDA-MB-231 (from 3.8 to 6.9 folds) compared to the untreated cells 
(Figure 2.4). The caspase-9 was also significantly (p< 0.05) activated after the pentapeptide 
treatment in MCF-7 (from 2.2 to 2.7 folds) and MDA-MB-231 (from 2.0 to 2.2 folds) cells 
(Figure 2.5). 
Caspase cascade is generally recognized as a hallmark of cells undergoing apoptosis. 
Caspases are group of cysteine proteases dividing into two sub-categories including effector 
caspases (such as caspase-3 and -7) and initiator caspases (such as caspase-8 and -9) (Tao et al 
2007). Two major apoptotic mechanisms including death receptor-dependent and mitochondria-




al., 1998). The caspase-3 or -7 are activated to cleave various cytoplasmic or nuclear substrates 
including DNAse which lead to the characteristic morphological changes and DNA 
fragmentation (Degen et al 2000; Stroh and Schulze et al 1998; Casciola et al 1995). Figure 2.3 
indicates that the caspase-3/7 activities in cells treated with pentapeptide increased significantly 
(p< 0.05) compared to control treatments with medium alone. Since MCF-7 is a caspase-3-
deficient breast cancer cell line, the results suggest that effector caspase-7, a sub-family member 
of caspase-3, plays indispensible role in MCF-7 cells during apoptosis. Previous studies have 
shown its role in apoptosis of caspase-3-deficient MCF-7 cells, (Hu et al., 2001; Janicke et al., 
1998; Twiddy et al., 2006). The activations of caspase-3/7 were observed in both cell lines after 
treatment with pentapeptide from 72 and 96 hrs which is consistent with the resulting 
morphological changes and the DNA fragmentation. Therefore, the results suggested that 
pentapeptide-induced MCF-7 and MDA-MB-231 cells death were involved in a mechanism of 
caspase-dependent apoptosis.  
To further investigate the features of caspase-dependent apoptosis in pentapeptide treated 
human breast cancer cells, the caspase-8 and caspase-9 levels in MCF-7 and MDA-MB-231 cells 
were evaluated. In the current study, the activated caspase-8 and -9 in cells reacted with 
aminoluciferin-labeled substrates and the relative concentrations were determined by measuring 
the luminescence intensities. Caspase-8 is activated through extrinsic pathway by interactions 
between ligands and death receptors. Caspase-9 is involved in intrinsic pathway and activated 
due to the mitochondrial cytochrome c leakage (Kumar 1999). The results showed that 
pentapeptide activates caspase-8/-9 and induced apoptosis in MCF-7 and MDA-MB-231 cells 
(Figures 2.4 and 2.5). These results suggest that penta eptide triggers apoptosis via a 





In conclusion, by evaluating the apoptotic features of pentapeptide treated human breast 
cancer cells (MCF-7 and MDA-MB-231) including morphological changes, fragmented DNA, 
and activation of caspases, the results in the current chapter demonstrated that the pentapeptide 
induces cell death in human breast cancer cell lines through apoptosis. The pentapeptide may be 
a potential anti-breast cancer agent or future alterna ive for current drug therapies when the 
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Figure 2.1 (a,b,c,d). Effect of pentapeptide on the morphology of MCF-7 and MDA-MB-
231 cells. 
Figure 2.1a.Morphology of MCF-7 cells cultured with media and observed after 72 hr 
incubation (control).  
Figure 2.1b.Morphology of MCF-7 cultured in the presence of pentapeptide (1000 µg/mL) 
and observed after 72 hr incubation 
Figure 2.1c.Morphology of MDA-MB-231 cells cultured with media and observed after 72 
hr incubation (control).  
Figure 2.1d.Morphology of MDA-MB-231 cells cultured in the presence of pentapeptide 
(1000 µg/mL) and observed after 72 hr incubation.  
All cell morphology were observed using a phase contrast microscopy (magnification: 200) and 
photos were taken using AmScope Color Digital Camer (MD 1000-CCD). 
All arrows point to the retracted and round cells which were undergoing apoptosis. 
Figure 2.1a Figure 2.1b 
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Figure 2.2 (a,b,c,d). DNA Fragmentation of pentapeptide treated MCF-7 and MDA-MB-
231 cells.  
Figures 2.2a.MCF-7 cells grown in media and observed after 72 hr.  
Figures 2.2b.MCF-7 cultured in the presence of pentapeptide (1000 µg/mL) and observed 
after 72 hr incubation.  
Figures 2.2c.MDA-MB-231 cells grown in media and observed after 72 hr.  
Figures 2.2d.MDA-MB-231 cultured in the presence of pentapeptide (1000 µg/mL) and 
observed after 72 hr incubation. 
All cells were stained using a Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL)-based DNA fragmentation kit and observed using a confocal microscope (Ex/Em = 
488/520 nm for FITC/green/apoptotic, and 488/623 nm for PI/red/rhodamine). 
All arrows point to the areas emit green light which reflect the fragmented DNA. 
Figure 2.2a Figure 2.2b 











Figure 2.3. The relative intensity of activated caspase-3/7 in pentapeptide (1000 µg/mL) 
treated MCF-7 and MDA-MB-231 cells after incubation for 72 and 96 hours.  
The cells cultured with media alone and genistein (400 µg/mL) are negative and positive control, 
respectively. Values are means ± standard deviation of three determinations. Values with the 















































Figure 2.4. The relative intensity of activated caspase-8 in pentapeptide (1000 µg/mL) 
treated MCF-7 and MDA-MB-231 cells after incubation for 72 and 96 hours.  
The cells cultured with media alone and genistein (400 µg/mL) are negative and positive controls, 
respectively.Values are means ± standard deviation of three determinations. Values with the 

















































Figure 2.5. The relative intensity of activated caspase-9 in pentapeptide (1000 µg/mL) 
treated MCF-7 and MDA-MB-231 cells after incubation for 72 and 96 hours.  
The cells cultured with media alone and genistein (400 µg/mL) are negative and positive controls, 
respectively. Values are means ± standard deviation of three determinations. Values with the 




















































Evaluation of molecular targets in pentapeptide-induced apoptotic pathways in human 
breast cancer cell models (MCF-7 and MDA-MB-231) 
Ruiqi Li, Navam Hettiarachchy, Mahendran Mahadevan 
Abstract 
Bioactive peptides derived from food sources with anti-proliferative properties against cancer 
have drawn more attention in recent years. A pentapeptide derived from rice bran was shown its 
anti-proliferative activities on human breast cancer cell lines via apoptosis. Evaluating the levels 
of various critical molecular targets was considere an effective mean to understand the 
underlying pathways involved in cell apoptosis after c rtain anti-cancer treatments. Thus, in this 
chapter, the objective was to investigate the apoptotic pathways of pentapeptide-induced 
apoptosis in breast cancer cell models (MCF-7 and MDA-MB-231) by determining the 
expression of various biomarkers. The levels of molecular targets (p53, COX-2, TNF-α, Bax, 
Bcl-2, Fas, and erbB-2) were evaluated by ELISA kits. Significant decreases in levels (p < 0.05) 
of COX-2 and increases in levels (p < 0.05) of p53 were detected after treatment with 
pentapeptide from 72 to 96 h. Significant (p < 0.05) decreases in the levels of Bcl-2 and erbB-2 
and increases in the levels of TNF-α and Bax were also detected after pentapeptide treatment 
from 72 to 96 h. The results suggest that pentapeptide inhibits growth of human breast cancer 
cells by introducing apoptosis through a caspase-dep ndent pathway. Pentapeptide stimulated the 
levels of p53 in both cells lines and may also suppress the COX-2 in ER-positive breast cancer 
cells such as MCF-7 by regulating estrogen synthesis. The pentapeptide also amplifies apoptotic 






 Studies have proven that various downstream signaling factors including the nuclear 
factor-κB (NF-κB), the Fas, the inhibitor of apoptosis proteins (IAP), and the mitogen-activated 
protein kinase (MAPK) family can mediate the process of apoptosis (Simstein et al 2003). As 
important biological indicators of cancer status and progression for the physiological state of the 
cell at a specific time, those molecular targets represent powerful tools for monitoring the course 
of cancer and gauging the efficacy and safety of novel therapeutic agents. 
              TNF-α is a naturally occurring cytokine secreted by cells of the immune system and 
other systems. This unique property has led to numerous studies of tumor necrosis factor (TNF) 
as a chemotherapeutic agent and apoptosis-inducing agent. TNF can activate both apoptotic 
pathways and survival pathways inside the cell. TNF-α has two receptors, p55 (TNFR1) and p75 
(TNFR2), with most apoptotic pathways mediated through p55.  
             Fas, a member of the TNF, is located on the cell surface and is activated by its ligand 
(Fas L) binding (Keane et al 1996). Fas forms death-inducing signaling complex (DISC), which 
finally leads to the activation of effecter caspases (Chopin et al 2002; Chen and Lin 2004). 
Studies have reported that anticancer drugs activate apoptosis in breast cancer cells by inducing 
the expression of death receptor ligands, such as Fas ligand (FasL) (Fulda et al2001).  
The Bcl-2 family proteins are considered a vital contr l point of apoptosis by regulating 
the release of cytochrome C and the activation of caspase-9. The subfamilies of Bcl-2 proteins 
include anti-apoptotic proteins (Bcl-2, Bcl-XL, Mcl-1, Bfl- 1/A1, Bcl-W, Bcl-G) and pro-
apopotic proteins (Bax, Bak, Bok, Bad, Bid, Bik, Bim, Bcl-XS, Krk, Mtd, Nip3, Noxa, Bcl-B) 
(Danial 2007). Bax-like death factors such as Bax, Bak, and Bok/Mtd induce apoptosis by 




generally classified as Bcl-2-like survival factors. These anti-apoptotic proteins are located on 
the outer mitochondrial membrane and protect the cells by forming heterodimers with pro-
apoptotic proteins (Borner 2003). The interactions between Bcl-2 family proteins affect cellular 
sensitivity to apoptosis and the ratio of pro-apoptotic proteins and anti-apoptotic proteins 
determines the fate of cells. The Bcl-2 proteins also interact with caspases in a mitochondrial-
independent pathway and play an important role in the activation of caspase-9 (Gross et al 1999).  
               Cyclooxygenase (COX) is an important e zyme in charge of formation of prostaglandin 
H2 from arachidonic acid. It has received considerabl  attention due to its multiple roles in 
human cancers development. The effect of COX-2 on cell growth results from the increased 
production of PGE2 and PGF2, which contributes to the cell proliferation (Bandopadhyay et al 
1987). In addition, the COX-2 suppresses the apoptosis by changing the cellular levels of 
antiapoptotic and proapoptotic proteins. In a furthe  step of cancer development, COX-2 also 
stimulates the invasion of cancerous cells to other tissues.  
              The purpose of this study is to quantify the levels of molecular targets (p53, COX-2, 
TNF-α, Fas, Bax, Bcl-2, and ErbB-2) in pentapeptide treated human breast cancer cells. This 
study provides insight on the molecular mechanism of action and apoptotic pathways of the 
pentapeptide against breast cancer cell lines and some preliminary results on it therapeutic/drug-
like property. 
 
Materials and Methods 
Materals. Human breast cancer cell lines (MCF-7 and MDA-MB-231), Leibovitz's L-15 
Medium, and Eagle's Minimum Essential Medium were purchased from ATCC. Bovine insulin, 
fetal bovine serum (FBS), Trypan blue, and genistein were purchased from Sigma (St. Louis, 




supplied by Abcam Plc. (Cambridge, MA, USA). The human COX-2 and Bax ELISA kits were 
supplied by Enzo Life Science Inc. (Farmingdale, NY, USA). The TNF-α and Fas human ELISA 
kits were purchased from Thermo Fisher Scientific In . (Waltham, MA, USA) and RayBiotech 
Inc. (Norcross, GA, USA), respectively.  
 
Methods. 
Cell culture. The human breast cancer cell lines (MCF-7 and MDA-MB 231) were cultured 
following steps described in Chapter 1, Methods-Cell culture. The MCF-7 cells were cultured in 
a 75 cm2 flask with Eagle's Minimum Essential Medium supplied with 0.01mg/mL bovine 
insulin and 10% FBS. Then, cells were grown in a humidified 5% CO2 incubator at 37°C for 
around 7 days and reached 80 to 90% fully confluent (around 5 x 106 cells) before collecting 
cells for further assays. The MDA-MB-231 cells were cultured in a canted neck 75 cm2 flask (to 
maintain the inside atmosphere in the flask) with Leibovitz's L-15 Medium including 10% FBS 
and incubated at 37°C in a humidified incubator.  
 
Determination of levels of p53, COX-2, TNF-α, Fas, Bax, Bcl-2, and ErbB-2. The levels of 
TNF-α, Bax, Bcl-2, COX-2, p53, Fas, and ErbB-2 in pentapeptide-treated MCF-7 and MDA-
MB-231 cells were determined using respective human ELISA kits (sensitivity: range 1.0 to 70 
ng/mL) following the company protocols under same principle. Cells were cultured and treated 
with pentapeptide (1000 µg/mL) for 72 and 96 hr. This concentration was used in all 
experiments that determining the levels of molecular targets. The cell lysates were prepared 
using lysis buffer and placed in 96-well plates coated with monoclonal detective antibodies and 




peroxidase conjugated streptavidin was added to bind to the antibodies in respective wells and 
the plate was then incubated for 1 hr. The substrate reagent was added to each well and the 
absorbances were measured at 450 nm using a microplate reader. The concentrations of p53, 
COX-2, TNF-α, Bax, Bcl-2, Fas, and ErbB-2 were determined by standard curves plotted using 
standard proteins. 
 
Data Analysis. All the treatments in the ELISA assays were conducted in triplicates. The data of 
levels of p53, COX-2, TNF-α, Fas, Bax, Bcl-2, and ErbB-2were analyzed by analysis of variance 
(ANOVA) using the Statistical Analysis System (SAS 9.2 2000, SAS Institute Inc., Cary, N.C., 
U.S.A.). The Fisher’s protected least significant difference (LSD) test was conducted to separate 
the means at P ≤ 0.05.  
 
Results and Discussion 
Expression of p53 and COX-2 in pentapeptide treated human breast cancer cell lines. To 
further investigate the possible mechanisms of pentapeptide-induced apoptosis in MCF-7 and 
MDA-MB-231 cells, the expressions of p53 (a tumor suppressor) and COX-2 (potential target 
for prevention and treatment of breast cancer) were ass ssed using ELISA assays in the presence 
of the pentapeptide (1000 µg/mL). Significantly (p< 0.05) increased levels of p53 were observed 
after 72 and 96 hrs of incubation with pentapeptide in both cell lines (Figure 3.1). However, the 
pentapeptide showed significant (p< 0.05) down-regulation on COX-2 levels in MCF-7 cells 
while no significant (p> 0.05) decreased levels of COX-2 in MDA-MB-231 were observed 




In an attempt to identify the possible mechanism of apoptosis in MCF-7 and MDA-MB-
231 cells in response to pentapeptide, the expression  of p53 and COX-2 were evaluated after 
pentapeptide treatment. It is widely known that p53is a tumor suppressor gene involving in cell-
cycle regulation and the induction of apoptosis by mediating the ratio of Bax (pro-apoptotic 
protein) to Bcl-2 (anti-apoptotic protein) (Mercer t al 1992; King and Cidlowsky 1998). The 
p53 protein helps in repairing the damaged DNA to cause G1 arrest and avoid the cancerous cell 
proliferation. Studies have suggested that the up-regulation of the p53 protein is in accordance 
with growth inhibition of cancerous cells when exposed to various anti-cancer agents (Chopin et 
al 2002; Cui et al 2007; Sun 2006; Wang et al 2004; Kuo et al 2005). In our study, the expression 
of p53 increased significantly (p< 0.05) in pentapeptide treated MCF-7 and MDA-MB-231 cells 
and suggests that pentapeptide up-regulates the activated p53 which may either trigger the onset 
of DNA repair or induces the apoptosis via mitochondrial-dependent pathway by regulating the 
levels of downstream molecules such as Bax, Bcl-2, and Fas. Thus, further investigation is 
needed to indentify the actual role of p53 in pentapeptide-mediated apoptosis in MCF-7 and 
MDA-MB-231 cells.  
COX-2 (Cyclooxygenase-2) is being intensively evaluated as a pharmacologic target for 
both the prevention and treatment of cancer. Studies have shown that high expression of 
prostaglandin (PG) detected in many types of cancers and enhanced PG synthesis may contribute 
to carcinogenesis via stimulation of cancer cell proliferation (Howe and Dannenberg 2002). 
Since the primary role of COX-2 in PG production as a critical synthase, studies has been carried 
out to design COX-2 inhibitors can be effective in treating breast tumors (Singh and Lucci 2002). 
Other studies also suggest that COX-2 over-expression may result in the suppression of pro-




research, the pentapeptide displayed a down-regulating effect on COX-2 level in MCF-7 cells; 
while the COX-2 level remained unchanged in a MDA-MB-231 cell line. These results 
suggested that pentapeptide suppress the level of COX-2 which leads to the cell growth 
inhibition via decreasing of estrogen levels in an Estrogen Receptor (ER)-positive MCF-7 cell 
line; however, pentapeptide has no effect on regulating COX-2 level in an ER-negative MDA-
MB-231 cell line. This result is agree with the previous study by Harris et al (1999), who 
suggested that PGs may also stimulate proliferation indirectly via increased estrogen 
biosynthesis in breast tissue. 
 
Pentapeptide induced apoptosis is promoted via a TNF-α and Fas-dependent pathway and 
the activation of caspase-8.To assess whether a death receptor-mediated pathway is involved in 
pentapeptide-induced apoptosis, the TNF-α and Fas protein levels were determined in MCF-7 
and MDA-MB-231 cells after exposure to the pentapeptid . TNF-α levels increased significantly 
(p < 0.05) after pentapeptide treatment for 72 and 96 hrs compared to negative controls (cell 
lines cultured only with fresh media) (Figure 3.3). Even though MCF-7 has shown significantly 
(p < 0.05) lower TNF-α concentrations than in MDA-MB-231 cells, there were more folds of 
TNF-α activated in MCF-7 (3 folds) than in MDA-MB-231 cells (1.3 to 1.5 folds) after 
incubation in the presence of pentapeptide (1000 µg/mL) for 72 and 96 hrs. The positive control, 
genistein resulted in significant (p < 0.05) increas s in Fas levels in MCF-7 and MDA-MB-231 
cells, and significant (p < 0.05) Fas increases were observed in pentapeptide treated cells in a 
time-dependent manner (Figure 3.4). 
TNF and Fas are considered members of the death domain receptors and they activate 




have demonstrated that MCF-7 cells are sensitive to TNF-induced apoptosis and that TNF-α is 
an effective inducer of apoptosis in MCF-7 cells (Chopin et al 2004; Burow et al 1999; Burow et 
al 1998; Cai et al 1997; Tewari and Dixit 1995; Jeoung et al 1995). The TNF- and Fas-induced 
apoptotic pathway activated via the interaction of TNF-receptor (TNFR)-associated death 
domain (DD), leads to the recruitment of Fas-associated death domain (FADD) (Rath et al. 1999). 
In turn, the FADD binds pro-caspase-8 and the activted caspase-8 triggers a protease cascade 
leading to apoptosis in cells (Degterev et al 2003). Studies have shown some anticancer agents 
such as ellipticine, caffeic acid phenethyl ester, doxorubicin, and camptothecin initiate the 
apoptosis via increasing Fas expression and recruiting death domain receptors such as FADD 
(Kuo et al 2005; Watabe et al 2004; Boesen et al 1999; Fulda et al 1997). In this study, 
pentapeptide treatment induced the increases in levels of TNF-α, Fas, and Caspase-8 in MCF-7 
and MDA-MB-231 cells. These data suggest that the pentapeptide stimulated apoptosis by 
inducing death receptor-mediated pathway.  
 
The mitochondrial-dependent pathway is activated by changing the Bax/Bcl-2 ratio 
involving the activation of caspase-9.To determine whether the mitochondrial apoptotic 
pathway is involved in pentapeptide induced apoptosis in MCF-7 and MDA-MB-231 cells, the 
expression of anti-apoptotic protein (Bcl-2) and pro-apoptotic protein (Bax) were investigated 
for indicated times (72 and 96 hr) after pentapeptide (1000 µg/mL) treatment. Significant (p < 
0.05) increases in Bax expression and decreases in Bcl-2 levels were observed in pentapeptide 
treated MCF-7 and MDA-MB-231 cells after 72 and 96 hr compared to the untreated cells 
(Figures 3.5 and 3.6). The expressions of activated Bax increased significantly (p < 0.05) in 




Furthermore, more decreases in Bcl-2 level in MDA-MB 231 (from 6.5 to 16.8 ng/mL) than 
MCF-7 (from 11.0 to 12.1 ng/mL) were observed along with prolonged incubation time from 72 
to 96 hr.  
The mitochondrial-mediated apoptotic pathway is activ ted through the disruption of 
mitochondrial membrane potential leading to the change of permeability by the opening of 
transition pores and release of cytochrome c (Shim et al 2007; Schrivastava et al 2006; Kallio et 
al 2005; ). Then, caspase-9 activates effector caspase-3, -7, and -6, which results in the activation 
of subsequent apoptosis (Pirnia et al 2002). The Bcl-2 family proteins, including pro-apoptotic 
proteins and anti-apoptotic proteins, play a curial role in determining the ultimate fate of cells 
and the ratio of Bax to Bcl-2 is a critical element i  apoptosis regulation. The pro-apoptotic 
protein (such as Bax, BAD, Bak, and Bok) inserts ino the mitochondria membrane and release 
the cytochrome c via forming a large channel, whereas the anti-apoptotic proteins including Bcl-
2, Bcl-xL, and Bcl-w could prevent this process (Kirkin et al 2004). 
Previous studies have demonstrated the importance of Bax/Bcl-2 ratio in regulating the 
mitochondria-mediated apoptotic pathway in human breast cancer models (Shim et al 2007, Cui 
et al 2007; Pozo-Guisado et al 2005; Hu et al 2002; Leung and Wang 1999). Our data showed 
that pentapeptide treatment increased the expression of Bax while down-regulating the Bcl-2 
levels, which happened along with the increased levels of caspase-9 and apoptosis in MCF-7 and 
MDA-MB-231 cells. Therefore, these results clearly indicate that the mechanism of 
pentapeptide-induced apoptosis by mitochondrial-mediat  pathway involves the mitochondrial 





Pentapeptide down-regulates the ErbB-2 expression in human breast cancer cell models. 
To study the possible role of ErbB-2 in pentapeptide induced apoptosis in human breast cancer 
cell lines, the ErbB-2 levels in MCF-7 and MDA-MB-231 were determined using ELISA assay. 
The pentapeptide lead to significant (p < 0.05) decreases in levels of ErbB-2 in both cell lines. 
Further, more down-regulating effects on ErbB-2 leve s in MCF-7 cells (from 1.4 to 2.0 folds) 
than MDA-MB-231 (from 1.1 to 1.6 folds) were observd after pentapeptide treatment (Figure 
3.7). ErbB-2 is a member of receptor tyrosine kinases. Its over-expression results in the 
resistance to apoptosis which may lead to the failure of chemotherapy in cancer cells (Roskoski 
2002). The high expression of ErbB2 promotes cell growth by activation of Akt (a 
serine/threonine kinase), which inactivates pro-apoptotic proteins such as Bax, Bad, and caspase-
9 through phosphorylation (Zhou and Hung 2003). Previous studies suggest that down-regulation 
of ErbB-2 could efficiently suppress the breast tumor cell growth (Wang et al 2007; Xia et al 
2006; Lee et al 2002; Daly et al 1997). The results of MCF-7 and MDA-MB-231 cells treated 
with pentapeptide suggest that pentapeptide may enhance the apoptotic signal by suppressing the 
expression of ErbB-2.  
 
Conclusion 
There are two apoptotic pathways involved in pentapeptide-induced apoptosis in human 
breast cancer cell lines. In one pathway, the apoptosis is activated after the increased Bax/Bcl-2 
ratio leads to the release of cytochrome c in mitochondria-mediated pathway. In the second 
pathway, pentapeptide induces apoptosis via death rceptor-mediated pathway by stimulating the 
expression of TNF-α, followed by forming the death-inducing signaling complex (DISC) 
through Fas expression and the activation of caspase-8. The pentapeptide may amplify apoptotic 




in both cells lines and may also suppressed the COX-2 in ER-positive breast cancer cells such as 
MCF-7 by regulating the estrogen synthesis. The findings in this study indicate the potential 
therapeutic value of this pentapeptide and further research in animal tumor models is necessary 
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Figure 3.1. The levels of p53 in pentapeptide (1000 µg/mL) treated MCF-7 and MDA-MB-
231 cells after incubation for 72 and 96 hours.  
The cells cultured with media alone and genistein (400 µg/mL) are negative and positive control, 
respectively. Values are means ± standard deviation of three determinations. Values with the 














































Figure 3.2. The levels of COX-2 in pentapeptide (100  µg/mL) treated MCF-7 and MDA-
MB-231 cells after incubation for 72 and 96 hours.  
The cells cultured with media alone and genistein (400 µg/mL) are negative and positive control, 
respectively. Values are means ± standard deviation of three determinations. Values with the 
















































Figure 3.3. The levels of TNF-α in pentapeptide (1000 µg/mL) treated MCF-7 and MDA-
MB-231 cells after incubation for 72 and 96 hours.  
The cells cultured with media alone and genistein (400 µg/mL) are negative and positive controls, 
respectively. Values are means ± standard deviation of three determinations. Values with the 
















































Figure 3.4. The levels of Fas in pentapeptide (1000 µg/mL) treated MCF-7 and MDA-MB-
231 cells after incubation for 72 and 96 hours.  
The cells cultured with media alone and genistein (400 µg/mL) are negative and positive controls, 
respectively. Values are means ± standard deviation of three determinations. Values with the 














































Figure 3.5. The levels of Bcl-2 in pentapeptide (100  µg/mL) treated MCF-7 and MDA-MB-
231 cells after incubation for 72 and 96 hours.  
The cells cultured with media alone and genistein (400 µg/mL) are negative and positive controls, 
respectively. Values are means ± standard deviation of three determinations. Values with the 















































Figure 3.6. The levels of Bax in pentapeptide (1000 µg/mL) treated MCF-7 and MDA-MB-
231 cells after incubation for 72 and 96 hours.  
The cells cultured with media alone and genistein (400 µg/mL) are negative and positive controls, 
respectively. Values are means ± standard deviation of three determinations. Values with the 












































Figure 3.7. The levels of ErbB-2 in pentapeptide (1000 µg/mL) treated MCF-7 and MDA-
MB-231 cells after incubation for 72 and 96 hours.  
The cells cultured with media alone and genistein (400 µg/mL) are negative and positive controls, 
respectively. Values are means ± standard deviation of three determinations. Values with the 



















































This study demonstrated that a pentapeptide with a sequencing of EQRPR shows anti-
tumor activities on human breast cancer cells (MCF-7 and MDA-MB-231) through apoptosis, 
but has no cytotoxic effect on normal human breast cells (HMEC). There are at least two 
apoptotic pathways involved in pentapeptide-induced apoptosis. In one pathway, the apoptosis is 
activated after the increased Bax/Bcl-2 ratio which leads to the release of cytochrome c in 
mitochondria-mediated pathway. In the second pathway, the pentapeptide may induce apoptosis 
via death receptor-mediated apoptotic pathway by stimulating the expression of TNF-α, followed 
by forming the death-inducing signaling complex (DISC) through Fas expression, which results 
in the activation of caspase-8. The pentapeptide stimulated the levels of p53 in both cells lines 
and may suppress the COX-2 in ER-positive breast cancer cells such as MCF-7 by regulating the 
estrogen synthesis. The pentapeptide may also amplify a optotic signals by down-regulating the 
expression of ErbB-2. The findings in this study indicate potential therapeutic value of 
pentapeptide and further research in animal tumor models is necessary to confirm its anti-cancer 
activity in vitro. The impact of this study provides information on cell specific pathways affected 
by this pentapeptide and could open avenues for the use of the pentapeptide as a nutraceutical 
diet/drug for breast cancer prevention. In addition, this research provides insight on the 
molecular mechanism of action of the pentapeptide against human breast cancer cells and results 
on its potential drug-like property. The production f this pentapeptide is less expensive than 
general cancer drug and could be a promising alterativ  strategy to current expensive anti-cancer 
therapies.  
 
 
 
